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Abstract
1.1 Deutsch
CD2, auch E rosette receptor, LFA2 (leukocyte function antigen) und T11
genannt, ist ein membranständiges Glykoprotein und gehört zur Immun-
globulin Superfamilie. Es ist ein früher T-Zell Marker und wird auch auf
NK-Zellen exprimiert. In vivo bindet humanes CD2 seinen Liganden CD58
(LFA3) an Antigen Präsentierenden Zellen und ermöglicht dadurch T-Zellen,
auf sehr geringe Antigen Konzentrationen zu reagieren. Gleichzeitig werden
durch diese Interaktion kostimulatorische Signale in T-Zellen induziert, die
an der Regulation der Zytokin-Produktion beteiligt sind, Zytolyse vermit-
teln, Apoptose von aktivierten peripheren T-Zellen inhibieren und T-Zell
Anergie regulieren.
Ziel der Studie war es, die Wirkung von CD2 Stimulation auf T-Zellen, vor
allem CD4 positive Helferzellen, auf mRNA und Protein Expression zu un-
tersuchen, da viele Mechanismen in diesem Zusammenhang noch nicht aus-
reichend geklärt sind.
Aufgereinigte CD4+ /HLADR- /CD25- T-Zellen wurden bereits mit CD2
Antikörpern stimuliert, und mit Hilfe von Amplichip mRNA expressions-
Arrays wurden Veränderungen der mRNA Expression im Vergleich zu un-
stimulierten, sowie zu Anti-CD3 stimulierten CD4+ /HLADR- /CD25- T-
Zellen analysiert. Kandidaten-Gene mit deutlich unterschiedlichem mRNA
Expressionslevel wurden für weitere Untersuchungen mit Hilfe von TaqMAN
Assays ausgewählt.
In dieser Studie wurden einige Gene, deren unterschiedliche mRNA Expres-
sion mittels TaqMAN bestätigt wurde und für deren Proteine kommerzielle
Antikörper zu Verfügung stehen, genauer untersucht. Die in diesem Zusam-
menhang untersuchten Gene, beziehungsweise Proteine sind:
CD200 (OX2/MOX2): Teil der Immunglobulin Familie, und ein Zellober-
flächen Glykoprotein welches in lymphoiden, neuronalen und Endothelzellen
exprimiert wird. Während die mRNA Daten auf eine recht schnell induzierte
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Transkription hingewiesen haben, konnten wir in den Western Blot Experi-
menten jedoch kaum Protein nachweisen.
CD137L: Gehört zur Familie der Tumor Nekrose Faktor Rezeptoren und
liefert kostimulierende Signale an T-Lymphozyten. CD137 wird auf ak-
tivierten T-Zellen exprimiert und bindet den Liganden CD137L, den man
auf B-Zellen, Makrophagen und Dendritischen Zellen findet. Solche Interak-
tionen sind in die Antigen Präsentation und die Bildung von Zytotoxischen
T-Zellen involviert. Es war uns im Rahmen der Experimente möglich diesen
Liganden erstmals auf T-Zellen nachzuweisen, und die gesteigerte mRNA
Expression zumindest teilweise zu verifizieren, was eine mögliche neue Ein-
sicht in die Regulation von T-Zellen untereinander zulässt.
αPak (Pak1 Kinase): Mitglied der PAK Kinase Familie (bestehend aus 6
Isoformen), die unter anderem eine sehr wichtige Rolle in Signalwegen von
T-Zellen spielen. Unsere mRNA Daten zeigten eine gesteigerte Transkrip-
tion von Pak1 nach anti-CD2-Stimulation, die wir auch auf Protein Ebene
nachweisen konnten.
NCK 1/2: Ein SH2/3 Adaptor Protein, welches eventuell auch für den
CD2 Signalweg relevant sein könnte, da wir zumindest auf mRNA Ebene eine
leichte Steigerung nachweisen konnten. Die Proteinkonzentration hingegen
wird kaum durch CD2 Stimulation beeinträchtigt.
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1.2 English
CD2, also called E rosette receptor, LFA2 (leukocyte function antigen), and
T11, is a membrane associated glycoprotein and belongs to the immunoglob-
ulin superfamily. It functions as an early T-cell marker, and is also expressed
on NK-cells. In vivo, human CD2 binds its ligand CD58 (LFA3), situated on
APCs (antigen presenting cells), thus enabling T-cells to respond to very low
antigen concentrations. Simultaneously, CD2 induces co-stimulatory signals
in T-cells, which are involved in cytokine production, mediate cytolysis, in-
hibit apoptosis of activated peripheral T-cells and regulate T-cell anergy.
The goal of this study was to examine the effect of CD2 stimulation on
T-cells, particularly CD4 positive helper cells, via mRNA and protein ex-
pression patterns, to shed light on mRNA and protein expression levels dif-
ferentially upregulated upon αCD2 stimulation and to identify signalling or
effector molecules so far unknown to be involved in CD2 mediated T-cell
activation.
Purified CD4+ /HLADR- /CD25- T-cells were previously stimulated with
anti- CD2 antibodies and utilizing Amplichip mRNA expression arrays changes
in mRNA expression were compared to both unstimulated and anti-CD3
stimulated CD4+ /HLADR-/CD25- T-cells.
Candidate genes with differential mRNA expression levels were selected for
further analysis using TaqMAN assays.
In this study, 4 genes were further investigated for alteration in their respec-
tive protein levels following CD2 stimulation:
OX2 (CD200/MOX2): A member of the immunoglobulin super-family, and
a membrane associated glycoprotein expressed in lymphoid, neuronal and
endothelial tissue. While our mRNA data suggested an increased transcrip-
tion rate, we were not able to detect proportional amounts of protein during
the Western blot experiments to support these findings.
CD137L: A member of the TNF (tumor necrosis factor) receptor family,
responsible for delivering co-stimulatory signals in T-lymphocytes. CD137
is expressed on all activated T-cells and binds to its ligand CD137L which
is found on B-cells, macrophages and dendritic cells. This interaction is in-
volved in antigen presentation and in the development of cytotoxic T-cells.
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During this study, we were able to demonstrate the presence of this ligand
on T-cells for the first time, and confirmed the increased mRNA expression
rate, at least partly. This might give a new insight into the subject of self
regulating T-cell populations.
αPAK (Pak1 kinase): A member of the PAK kinase family (comprising
6 isoforms) which, among other functions, plays an important role in T-cell
signalling. Our mRNA data indicated an increase in mRNA transcription
upon CD2 stimulation, which we were also able to confirm on the protein
level.
NCK 1/2: A member of the SH2/3 adapter protein family, might be part of
the CD2 pathway, since we were able to show a slight increase in the mRNA
expression. The protein concentration, however, did only change little, if at
all, following CD2 stimulation.
Introduction
2.1 No Body is Perfect (The Immune System)
2.1.1 The Innate Immune System
The immune system in higher organisms such as mammals basically con-
sists of two separate compartments. One of them is the innate immune
system, which is based on cellular and chemical barriers, inflammation, and
the complement system. The skin of the human body for example poses
a physical and chemical barrier to microbes due to its keratinized layer of
water-impermeable epithelium, as well as an acidic pH level (around 5.5)
maintained on its surface, together with a vast amount of enzymes and an-
tibiotic chemical compounds (such as cathelicidin, ß-defensins, dermicidin,
psoriasin, etc.). Most of these antibiotic substances are produced in ac-
crine sweat glands, by epithelial cells and keratinocytes, or by an army of
specialized cells, which are harbored within the sub-epithelial connective tis-
sue (including mast cells, neutrophils, and macrophages) [1]. Monocytes
(e.g. macrophages) are able to recognize potential hazardous materials or
microbes using toll like receptors (TLR), and basically devour the intruder.
Receptor Ligand
TLR1 Bacterial lipopeptides
TLR2* Lipopeptides, lipotechoic acid, peptidoglycans
TLR3 Double-stranded RNA, polyinosine:cytosine
TLR4 LPS
TLR5 Flagellin
TLR6 Zymosan, lipopeptides
TLR7 Single-stranded viral RNA, imiquimod
TLR8 Single-stranded viral RNA, imiquimod
TLR9 Unmethylated CpG DNA
TLR10 unknown
Table 2.1: * TLR-2 cooperates with TLR-1 and TLR-6 to recognize lipotei-
choic acid, zymosan, and other ligands. TLR-5, TLR-7, TLR-8, and TLR-9
cooperate to recognize CpG DNA, ssRNA, and flagellin. [2]
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Another weapon and major part of the humoral response of the innate
immune system, is the complement system. This system consists of more
than 30 soluble proteins that are activated in a biochemical cascade trig-
gered by the binding of the glycoprotein C1 to one IgM or several IgG an-
tibodies, which recognize certain microbic surface molecules. The result of
this reaction is the recruitment of the membrane attack complex (MAC) to
the cell membrane of the pathogen which then basically pokes holes into the
microorganism, thus killing it.
Several functions of the innate immune system can be traced back to very
simple life forms such as protozoans, single cell organisms which roam the
earth for now over 2.5 billion years. This suggests that the innate immune
system is the evolutionary older part, since some of its features including
phagocytosis can be found in almost all living creatures even the simplest
and oldest ones. Even in starfish or sponges specialized phagocytic cells
patrol in and around their tissues to protect them from microbic foes. [3]
Another conserved and very important aspect of the immune system is the
discrimination between „self“ and „non-self“ which, in higher organisms such
as mammals, is achieved by specific surface molecules and pattern receptors.
2.1.2 The Adaptive Immune System
The younger and far more specific relative of the innate immune system is
the acquired or adaptive immunity, which is branched into a humoral and a
cellular compartment. The leading actors of the humoral branch are called
B-lymphocytes or B-cells that secrete antibodies, which bind to the surface
of foreign „non self“ substances or microbes, triggering an immune response.
The „B“ stands for Bursa fabricii, a specialized organ in birds, which is
their site of hematopoiesis, hence the name B-cell. In humans the site of
B-cell development is the bone marrow and the spleen, yet the „B“ in hu-
man B-cells does not stand for bone marrow. [4] B-cell development in the
bone marrow starts with so called common lymphocyte precursors (CLP)
which then differentiate into the first B-linage specific pro-B-cells followed
by a rearrangement in the immunoglobulin heavy chain characteristic for
pre-B-cells (see fig 2.1). These immature (ImmB) cells already express IgM
receptors. Upon activation B-cells secrete IgM antibodies (but are able to
isotype switch to IgG, IgA and IgE), which are usually the first antibodies
to be produced in an immune response and are able to activate the comple-
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ment system. Mature B-cells may further develop into plasma cells, which
then secrete antigen-specific IgG antibodies, which play a major role in the
immunological long term memory. The main task for these immune cells
is to produce immunoglobulins with a huge variety of antigen specificities,
which then circulate in the blood waiting for a victim in the form of foreign
substances or organisms. B-cell TLR signalling also plays an important part
in inflammatory responses, hence connecting the cell mediated (BCR) adap-
tive immune system to the humoral (antibody and TLR) part of the innate
immune system. [5]
2.1.3 Attack of the Clones (T-Cells)
The other part of the adaptive immune system is maintained by another cell-
population called T-cells. Like B-cells they originate from the bone marrow,
but then specialize and mature in the thymus gland, hence the name T-cell.
A small fraction of T-cells, however, is present in the fetal liver, which sug-
gests a role of the fetal liver in T-cell development as well. For a vast period
of time in the history of medicine, the thymus was thought to be a vestige
of evolution, just as the appendix, with no obvious assignment, and even
though the name roots in the Greek word for life force „thymos“ suggest-
ing some sort of importance, it took science until 1961 to discover its true
purpose. Experiments conducted by Francis Albert Pierre Miller [6] were
the first milestones in the research of the thymus and its crucial role in the
immune system. After these early discoveries, it soon became clear that the
thymus is responsible for the development of one of the main weapons of the
adaptive immune system: T-cells. There are two fundamental branches of
T-cells: cytotoxic T-cells (Tc or CD8+) and T helper-cells (Th or CD4+).
They undergo a sequential maturation, which starts with DN (CD4/CD8
double negative) thymocytes, entering the thymic parenchyma via the vessels
around the corticomedullary junction (see fig 2.1). The DN stage is further
partitioned into four substages: First the CD44+ CD25- (DN1) stage, fol-
lowed by CD44+ CD25+ (DN2), the CD44- CD25+ (DN3) and finally CD44-
CD25- (DN4) stage. Within the DN3 stage, a selection is made whether the
T-cells commit to the T-cell-receptor (TCR) αβ linage via pre-TCR (pT)
expression, or commit to the TCRγδ linage expressing TCRγδ. αβ lympho-
cytes are selected positively and negatively via their MHC interaction, while
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Figure 2.1: T- and B-cell development [7]
the γδ development and selection process is still under discussion [8]. Most
of the TCRγδ cells have neither CD4 nor CD8 on their surface, which makes
sense since the γδ T-cell receptor does not need a MHC context to bind and
recognize foreign substances, instead it binds to organic molecules (often
containing phosphorus atoms) in the same manner as antibodies do [9] [10].
The following DP (CD4/CD8 double positive) stage, in which the cells ex-
press both CD4 and CD8 on their surface, is characterized by the interaction
of DP cells with an MHC receptor of stromal cells, which leads to positive or
negative selection, as well as allelic exclusion at the TCRβ locus, termination
of pTα expression and the initiation of the V(D)J somatic recombination [9].
The V(D)J recombination, standing for Variable, Diverse and Joining gene,
is an important genetic mechanism for a T-cell to randomly assemble their
T-cell receptor in order to broaden the responsiveness to possible antigen
targets. The V(D)J recombination event is essentially the same for T- and
B-cell receptor, as well as for immunoglobulins. In T-cells the recombination
starts with the D-to-J recombination in the β chain of the TCR in which ei-
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Figure 2.2: basic overview of V(D)J recombination-events of immunoglobulin
heavy chains
ther Dβ1 segment joins one of the six possible Jβ1 segments, or alternatively
the combination of Dβ2 with one of the seven Jβ2. Next, the Vβ-to-DβJβ
recombination takes place with ultimately leaving a complex of Vβ-Dβ-Jβ
with the constant domain gene (Vβ-Dβ-Jβ-Cβ). Final splicing events delete
any remaining intervening sequences and the final construct is translated
into the TCR β chain (see Fig 2.2). After the completion of the β chain, the
α chain of the TCR is assembled in a similar way with the difference that
the α chain lacks the D segment, therefore the first step is the formation of a
VJ complex followed by the addition of the constant domain. Finally α and
β chains are assembled to the αβ-TCR which most T-cells carry. Successful
(positive selected) cells receive a survival and maturation signal and undergo
a change from DP to SP (single-positive), and from there on only bear CD4
or CD8 molecules, restricting CD4+ helper T-cells to MHC class II and cy-
totoxic CD8+ T-cells to MHC class I [7]. SP cells are then homed to the
medulla where they undergo a selection for the deletion of self-reactive T-
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cells, in a process called central tolerance. Cells which bear a receptor with
high affinity for host or „self“ peptides are sent into apoptosis to prevent po-
tential autoimmune reactions [9]. T-cells which fail to recognize MHC class
I or class II receptors, do not receive any survival or maturation signals and
die by programmed cell death as well. Compared to the vast number of cells
which start their development in the thymus gland, only a few cells endure
this harsh yet important selection process, and are then allowed to leave the
thymus via venules or lymphatic vessels and finally stand sentinel to defend
their host against foreign pathogens.
In this context, crosstalk between the adaptive and innate immunity is cru-
cial for the development of a full immune response to a pathogen (see figure
2.3), but also plays a major role in the progression of autoimmune diseases.
For a targeted response to the innumerous bacterial, fungal or viral invaders,
Figure 2.3: simplistic diagram showing the interaction between different im-
mune cells and their crosstalk [11]
T-cells have to rely on contact with other lineages of the immune system,
especially antigen-presentig cells (APC). Upon contact with the T-cell in the
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lymph nodes or the spleen, the APC then activates and in a broader sense
primes the T-cell for its task, the purge of the presented antigen.
This cell-cell contact is conducted via a so called immunological synapse (see
chapter 2.4.1) forming around the MHC-TCR receptor interaction. A cor-
rect and fitting MHC context has to be established in order to activate the
T-cell, which shortly after the first contact with the antigen, shifts into an ac-
tivated stage, meaning that organelles and the cytoskeleton are rearranged,
cell cycle progression is induced and finally clonal expansion starts. The
T-cell clones, armed with highly specific receptors for their assigned antigen
then drift through blood or lymphatic vessels searching for infiltrators and
infected or transformed cells carrying the target antigen in a MHC context.
Upon contact with their carefully selected target, another cytoskeletal rear-
rangement is induced via TCR signalling, allowing the T-cell to direct the
secretion of cytolytic substances or cytokines into the newly formed inter-
cellular cleft [12]. With this strategy, single T-cells are able to multi task,
meaning that they can simultaneously lyse an infected or transformed cell
while forming stimulatory immunological synapses with other cells of the
immune system, thanks to a rapid shift of their polarity via rearrangements
of their actin fibres.
2.2 Cells with Helper Syndrome (CD4+ Cells)
Contrary to CD8+ cytotoxic T-cells, CD4+ helper cells (Th) are not endowed
with any cytolytic potential whatsoever, therefore do not engage the intruder
directly, but rather guide, support and/or suppress other cells of the immune
system. Therefore, as the name suggests, the main role of CD4+ helper cells
is helping to balance the divergent and complex functions of the immune
system. Especially in autoimmunity and inflammatory diseases these helper
cells play a crucial role, since in these cases they often fail to maintain
the composure of an immune system which is frantically attacking a „self“-
peptide, or a harmless peptide which is mistaken for a hazardous pathogen
[13]. Within the helper cell population there are various subtypes, each
with a different task assigned. The first two subpopulations which were
identified in the late 1980s were Th1 and Th2 [14] and since then a few
new subclasses joined the list of CD4+ T-cells. While the first immune-cells
were identified and characterized by their expression of certain CD (cluster
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of differentiation) surface molecules, the new subclasses were classified by
their cytokine profiles and therefore their function within the meshwork of
immunology (see Fig 2.4).
Figure 2.4: Different subsets of CD4+ Cells with their distinctive cytokine
profile and origin [15]
The classification through cytokine production also helped to develop a
better understanding for the communication between cells of the immune
system and their linage commitment. Cytokines secreted from one cell rein-
forced its own development towards one specific helper-cell population and at
the same time inhibited the development into other cell types. These findings
of the early 90s from Mosmann et al. [14] as well as similar studies conducted
by Coffman in 1986 [16] laid the foundation of our modern understanding
of the complex development and maintenance of our immune system. Based
on their biological function, there is a basic distinction between regulatory
T-cells including nTreg (naturally occurring), iTreg (induced Treg), which
are important for the suppression and regulation of the immune system and
Th1, Th2, Th17, Tfh and Th9 cells, which play a major role in inflammatory
responses [13].
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2.3 Commitment Issues (CD4+ Subsets)
2.3.1 Th1
Segmentation of T-cells via cytokine excretion lead to the discovery of Th1
and Th2 helper cells, of which the former are characterized by their pro-
duction of pro-inflammatory cytokines, namely IFN-γ, TNF-α and TNF-
β [14] [13]. Besides their ability to promote IgG2a production in B-cells,
their main task is to defend the host against obligate intracellular pathogens
such as the potozoan parasite Leishmania major [13]. Apart from Leishma-
nia major, Th1 response and the resulting IFN-γ production is crucial for
the clearance of intracellular bacteria, such as Mycobacterium avium [17],
Listeria monocytogenes [18], Salmonella typhimurium [19], as well as fungal
parasites such as Cryptococcus neoformans [20], and viruses, such as herpes
simplex virus (HSV) [21] and influenza A virus [22]. Secondly, Th1 cells seem
to be very important in keeping the host free of tumors, which was shown
in in vivo mouse models by Micallef et al. [23]. It is an intricate balance
these cells must achieve between their important role in pathogen clearance,
defense against tumor cells, stimulation of the innate and T-cell immune
system, and on the other hand refraining from damaging the host by an ex-
cessive reaction leading to self reactivity and inflammatory diseases [13]. It is
known that Th1 cells play a leading role in the development of inflammatory
bowel disease (IBD) [24], diabetes mellitus (type 1 diabetes), graft rejection
in patients with bone marrow transplantation [25] as well as autoimmune
disorders such as rheumatoid arthritis (RA) [26].
2.3.2 Th2
The role of Th2 helper cells is mainly to produce IL-4, 5, 9, 10 and 13
as well as the rallying of eosinophils and the isotype switching of IgG1 to
IgE [14] [13]. In contrast to the tasks Th1-cells are assigned with, the Th2
response focuses more on a humoral response to foreign organisms, especially
when dealing with considerable big extracellular hostiles, such as nematodes
or helminthes. Within a Th2 response, large amounts of pathogen-specific
immunoglobulin are produced in order to deal with the intruder [27]. An-
other important task for Th2 cells is mucosal immunity in the lung, since an
exaggerated Th2 response might lead to chronic inflammation of the airways,
atopic asthma, as well as other allergy related pathologies ascribed to exces-
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Figure 2.5: A simplified model of the interactions between T helper 1 (Th1)
and Th2 responses [Source: http://journals.cambridge.org/ fulltextcontent/
ERM/ERM209/ S1462399400002143sup007.pdf]
sive Th2 functions [28]. It is thought that the subset of Th2 cells evolved
after their relatives, the Th1 cells, since the targets of the Th2 response seem
to be of more recent origin [13] (see Fig 2.5).
2.3.3 Th17
Another important part of the helper-cell population is embodied by a sub-
class called Th17, which presumably plays an important role in autoimmune
tissue injury. As the name suggests, they are defined by their expression
of Interleukin 17 (IL-17), namely IL-17A, E and F, as well as IL-21 and
22 [13]. While their status as an independent linage is widely accepted due
to their central role in experimental autoimmune encephalomyelitis (EAE),
collagen-induced arthritis (CIA) and inflammatory bowel disease (IBD) [29],
their common features and differences in the development with the Th1 and
Th2 linage is questioned. Two different models were proposed for Th17 de-
velopment: The first model suggested that Th17 cells share early stages with
the Th1 linage with both cell lines expressing IL-12 and IL-23 receptors as
a common precursor stage, followed by linage selection via the availability
of either IL-12 or IL-23. In contrast, the second model stated that the de-
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velopment is distinct from the Th1 linage, since pertaining to their role in
EAE and CIA, T-bet and STAT4 are essential for the development of these
diseases, whereas IL-12, IFN-γ and STAT1 are not. Several studies sup-
port the second model of Th17 development, since Weaver et al. [15] were
able to show that Th1-polarized cells were not able to produce IL-17 af-
ter stimulation with IL-23, proposing that Th1 cells are not responsive to
Th17 developmental signals. They furthermore showed that IFN-γ actively
suppresses Th17 development, indicating that they do not share a common
precursor [15]. The importance of Th17 mediated immunity was empha-
sized in several papers dealing with their role in specific infections such as
Listeria, Salmonella, Borrelia burgdoferi, Mycobacteriom tuberculosis, and
several fungal species, indicating that these T-effector-cells are triggered by
particular pathogens and are needed for their combating [13].
2.3.4 Treg
Treg cells are considered to be the regulators of the regulators, since their
assignment is to modulate the helper cell response posed by Th1 and Th2.
They split into nTreg (natural T regulators) and iTreg (inducible T regu-
lators, see Figure: 2.6), they are part of the CD4+ subset of lymphocytes,
undergo development in the thymus similar to Th cells, but both Treg lines
additionally express high levels of CD25 (α-chain of IL-2 receptor), CTLA-4
(cytotoxic T lymphocyte-associated antigen 4), GITR (glucocorticoid-induced
tumor necrosis factor receptor family-related gene), LAG-3 (lymphocyte ac-
tivation gene-3) [30], as well as the transcription factor Foxp3 (forkhead box
P3 transcription factor) [31].
iTreg populations further produce membrane-bound forms of TGF-ß and IL-
10 after stimulation via the TCR [13]. CD25+ CD4+ Tregs represent only
about 5-10% of the peripheral CD4 expressing T-cell population, which is
one reason why their function and affiliation is not yet fully defined. An-
other reason is the fact that surface markers such as CD25 and others listed
above are not strictly limited to Treg cells, since they are general markers
for activated T-cells, which makes it difficult to isolate them from other T-
cell populations. Recent studies, however, indicated their distinction and
specific role in the immune system especially for self-tolerance. The lack or
dysfunction of a normal Treg population by disruption of the Foxp3 gene for
example led to severe autoimmune reactions, such as inflammatory bowel
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Figure 2.6: Different types of T-cells which all originate in the thymus and
then develop into specialized immune-cells such as regulatory T-cells [32]
disease, allergy, and type 1 diabetes [31].
2.3.5 Tfh
A small subpopulation of helper cells is stationed in the follicular regions
and germinal centers, and the edge of B-cell zones, hence the name follicular
helper T-cells (Tfh).
These germinal centers (or GC) are sub-structures within secondary lym-
phoid tissues such as the spleen or the tonsils and are an important site for
B-cell development (see Fig.2.7) [34].Tfh are characterized by their increased
expression of the CXC-motive chemokine receptor 5 (CXCR5), also known as
the Burkitt- Lymphoma receptor 1 (BLR-1), which binds to the chemokine
CXCL13. This chemokine is highly expressed in B-cell zones, thus homing
Tfh cells to these centers [13].
A main task for CD4+ helper cells is the support of B-cell development by
promoting processes, important for humoral immunity, such as immunoglob-
ulin isotype-switching and the generation of memory B-cells. For a long time
it was thought that this was exclusive Th1/Th2 business, but recent studies
have shown that a different subclass of helper-cells is involved in this process
as well, i.e. follicular helper-T-cells [35]. Recent studies were able to illume
the role of this small subset of helper-cells, by pointing out the difference
between cytokine expression patterns between Th1, Th2 and Tfh. Tfh cells
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Figure 2.7: development and maturing of B-cells in the germinal centre [33]
produce IL-10 and Il-21 [34], which distinguishes them from Th1 and Th2.
Additionally, their independence of TGF-β and retinoid-related orphan re-
ceptors for differentiation makes them different from Th17 cells [36], leaving
them with an autonomous role as B-cell development helpers in the germinal
centers [13].
2.3.6 Th9
It is not clear yet, if Th9 cells actually are a fully differentiated effector cell
linage, since they share a lot of common features with Th2 cells. The main
difference seems to be the increased generation of the cytokine IL-9, hence
the name Th9, while the secretion of Th2 related cytokines like IL-4, IL-5
and IL-13 seems to be decreased. Additionally, they seem to lack the typical
transcription factor for Th2 cells, namely GATA-3, and Treg/Th17 specific
factors Foxp3 and RORct [37]. Whether these cells are an autonomous sub-
population or rather specialized Th2 cells has to be further investigated,
since there is no confirmed molecular marker ascribed exclusively to these
cells yet. Nevertheless, Th9 cells seem to play an important role in the im-
mune response to certain helminth infections [13], a task formally assigned
to Th2 cells.
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2.4 T-cell Activation
2.4.1 The Immunological Synapse
Activation of T-cells is a complex process, involving cytoskeletal changes and
rearrangements of the cell surface. An alteration of surface receptor patterns
leads to the formation of a so called „immunological synapse“ which is the
main interface for activation and communication between cells of the im-
mune system. The term „synapse“ is usually used for contact junctions of
neuronal cells with other neurons, muscle cells, glands, or sensory cells, and
has its origin in the Greek words for „syn“ (together) and „haptein“ (grasp
or grip). In this context, the term is used for the plane signalling-complexes
established between a T-cell and an APC, with the TCR-pMHC (peptide
bound MHC) complex forming the core of the synapse, also called central
supra-molecular activation cluster (c-SMAC). The TCR complex consists of
a TCRα and β chain, together with the CD3 complex composed of one γ,
one δ, two  and two ζ chains [38]. Additionally the c-SMAC also harbors
other signalling receptors including CD2, CD28, PCK-φ, CD4 or in case of
cytotoxic T-cells CD8 (see Fig 2.9). In order to stabilize the signalling com-
plexes formed in the c-SMAC domain, the surrounding rings of molecules in
the peripheral supra-molecular activation cluster (p-SMAC) contain leuko-
cyte function antigen-1 (LFA-1) and ICAM-1 adhesion proteins [39].
The formation of the synapse relies on TCR-signalling, which, with the
aid of co-stimulatory receptors and signals, leads to a reorganization of
the cytoskeleton and other receptors, finally resulting in the polarization of
the T-cell towards the antigen-presenting-cell (APC) and its peptide bound
MHC [40]. In contrast to synapses being formed by neuronal cells, which
are stable for years, the immunological synapse is considered to be formed
for a very brief period of time only. Lee et al. [42] even stated that constant
and tedious stimulation via the TCR it is not essential for T-cell activation,
which questions the belief of the central role of the immunologic synapse in
T-cell activation. Other studies support that statement by demonstrating
that T-cells internalize approximately 90% of their TCRs within thirty to
sixty minutes of the first contact with the pMHC [40]. Nevertheless, the im-
portance of the synapse was established in many surveys using biochemical
and genetic methods, regardless of its role in actual T-cell activation. One of
the first stages in TCR signalling is the phosphorylation of CD3 (see chapter
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Figure 2.8: The Immunological Synapse [41]
2.4.2), which leads to downstream activation of a variety of other signalling
pathways and different genes, resulting in considerable changes in the T-cell
protein and mRNA expression patterns and cell cycle progression [40].
2.4.2 CD3 signalling
As far as the TCR signalling complex is concerned, the assignment of the two
α and β chains as the binding site for antigens was discovered and described
first. Due to its polymorphic nature and relation to the immunoglobulin
superfamily it was evident that this was the site for antigen binding [43].
The role of CD3 remained elusive for a long time but was later discovered
to be the main signal transducer of the TCR complex. All CD3 chains,
in contrast to the two α and β chains, contain long cytosolic tails with at
least one immunoreceptor tyrosine-based activation motif (ITAM). On the
whole, there are 10 ITAM motifs situated on the cytosolic tails of different
CD3-chains, with one sitting on each CD3γ, δ and  tail, and six on the
homodimer CD3ζ [38]. With their cytosolic tails the CD3 molecules associate
with members of the T-cell-specific Src family of protein tyrosine kinases,
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Figure 2.9: CD3 chain phosphorylation upon contact with APC and Antigen
[http://www.reactome.org -> TCR signaling]
Fyn and Lck. Other molecules involved in T-cell activation include CD45
and CD4 (or CD8) with the tyrosine kinase Lck bound to their cytoplasmic
domain (see figure 2.9). Upon contact with a peptide bound MHC receptor,
the kinases Fyn and Lck phosphorylate the CD3-chain ITAM motifs, thus
creating docking sites for proteins carrying Src homology 2 (SH2) domains
such as the Syk-type kinase ZAP 70 (zeta chain-associated protein of 70
kDa) [12]. Furthermore, it is thought that upon TCR activation, CD3
undergoes a conformational change, exposing its proline rich region (PRR),
which makes it available for binding of SH3 domain carrying proteins such
as NCK (see chapter 2.8). Interestingly, this conformational change happens
before CD3ζ and  phosphorylation, which might indicate that the binding of
NCK is an important step for the further recruitment of kinases which then
accelerate the phosphorylation of the CD3-chains [43] [9]. It is not clear yet,
whether the phosphorylation of the ITAMs or the conformational change
of the CD3ζ chain (or both) are equally responsible for the forwarding of
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the signal. In addition, the co-receptor, whether it is CD4 or CD8, is also
necessary for the correct binding of pMHC thus bringing the bound Lck into
proximity of ZAP70 resulting in its phosphorylation and activation. The
now activated ZAP70 can bind to and activate a number of intracellular
signalling adaptor molecules, such as the linker for the activation of T-cells
(LAT) and the SH2 domain containing leukocyte phosphoprotein of 76 kDa
(SLP-76) [12]. These two adaptor proteins are crucial for TCR signalling,
since studies showed that a loss of function in one of these two genes led to
a dysfunctional TCR signalling [43].
2.4.3 The Role of CD2
Regarding T-cell activation and regulation, CD2 (formerly known as T11,
LFA-2 and E-rosette receptor) has not enjoyed as much attention and re-
search as CD3, therefore its role as a co-stimulatory molecule is not fully
disclosed so far. What is known is that CD2 is an approximately 55kDa
transmembrane surface glycoprotein expressed on T-cells and NK cells, im-
portant for adhesion in cell-cell contact [44], and it is responsible for the
ability of human T-cells to form rosettes with sheep erythrocytes - hence
the name E-rosette receptor. There are at least six known epitopes, among
which T11.1, T11.2 and T11.3 are the most important ones. The first two
epitopes (1 and 2) are expressed on resting T-cells whereas T11.3 is only ex-
posed on activated T-cells [45]. In vivo, CD2 (structure shown in Fig 2.10) is
able to bind to its ligand CD58 (LFA-3), which is widely expressed on many
cell types (including APCs and stromal cells) as well as to CD59, and CD48
(in rodents) [46] [44], contributing to adhesion and T-cell activation in two
ways: Firstly, the interaction between CD2 and CD58/CD48 (Kd 1 µM)
leads to cross linking between T-cell (in this case) and target cell surface
molecules [47], leading to a process called scanning [48]. „Scanning“ means
that the T-cell is able to attach to the APC in a manner, which still allows
it to move alongside the APC, frisking its counterpart for antigen bound
MHC molecules. Secondly, since CD2 is situated in the c-SMAC domain
of the IS in contrast to ICAM1 and LFA1 as mere adhesion molecules in
the pSMAC domain, CD2 is suggested that as a (co-) stimulatory molecule,
it contributes to the TCR-mediated activation of T-cells as well as other
pathways (see Fig 2.11). The loss of CD2 function leads to an immunosup-
pressive state in both rodents and humans, underlining its important part
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in the cellular immune response. In order to distinguish between a mere
Figure 2.10: Structure of CD2 and CD58
Source: PDB: 1QA9
http : //www.pdb.org/explore/explore.do?structureId = 1QA9
role as an adhesion molecule and actual involvement in T-cell activation, a
model has been suggested, which measures the rate of TCR internalization, a
process requiring a TCR-pMHC interaction, hence an engaged TCR. In gen-
eral, it was thought that there are specialized molecules for adhesion (such
as ICAM1/LFA1) and a separate set of co-stimulatory molecules interven-
ing with TCR signalling (such as CD28). CD2, albeit not a co-stimulatory
molecule such as CD28, has the ability to facilitate both adhesion to APCs
and stimulation of T-cells [49]. As a co-stimulatory receptor, it was demon-
strated that the binding of CD2 to CD58 leads to the activation of protein
tyrosine kinases (PTKs) in the cytoplasma, in particular LCK and FYN as
well as the Tec family kinase EMT/ITK/TSK [50]. This CD2 triggered ac-
tivation is dependent on Lck but independent of CD3ζ chain, underlining
the role of CD2 as a co-stimulatory receptor. In order to understand the
role of CD2 in cytoskeletal rearrangements, adhesion or activation, different
CD2 cytoplasmic tail interaction proteins were investigated. CD2 cytoplas-
mic tail-binding protein 1 (CD2BP1) is one of them and is an homolog to
the Schizosaccharomyces pombe cdc15 which is involved in actin-cytoskeletal
regulation [52] [53]. CD2BP1 has the ability to bind to CD2’s proline rich
sequences (PPLP) with a SH3 domain, but more importantly link CD2 to a
protein tyrosine phosphatase (PTP)-PEST. In mice CD2BP1/PSTPIP (the
equivalent of PTP-PEST) complexes are able to interact with WASP, which
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Figure 2.11: Heterophilic interaction of CD2 with CD58. MHC-TCR com-
plex is shown for comparison of molecular dimensions [Source: [51]]
is a key regulator for the actin cytoskeleton. Furthermore, Hutchings et al.
were able to show the interaction between the cytoplasmic, proline-rich tail
of CD2 and the actin cytoskeleton via the actin associated proteins CMS
(human CD2AP), CIN85 and CAPZ, underlining the role of CD2 in the ac-
tivation of T-cells [54].
A branch of T-cells situated at the mucosal lamina propria (LPTC) show an
increased level of IFN-γ expression after CD2 stimulation, due to phospho-
rylation and enhanced binding of STAT1 and STAT4 to the IFN-γ intronic
element. This leads to the conclusion that CD2 stimulation plays a very im-
portant role in the regulation of cytokine secretion in the gut, above all IFN-γ
which is associated with IBD [55]. Besides IFN-γ production in LPTC, CD2
is also able to induce the production of IL-2 in peripheral T-cell populations,
or enhance the production of IL-2 as a co-stimulatory receptor together with
the TCR [46].
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2.5 CD137L:
CD137L (also called 4-1BBL) is part of the tumor necrosis factor super-
family (TNFSF), thus called TNFSF9, and binds to its receptor CD137 or
4-1BB, which is part of the tumor necrosis factor receptor superfamily (TN-
FRSF), inducing co-stimulatory signals. This interaction plays a crucial role
in processes such as proliferation, apoptosis, and differentiation through the
interplay between APCs and other immune cells, such as T and B lympho-
cytes [56]. Similar to all other members of the TNF superfamily, CD137L is a
type II membrane protein with its C-terminus (containing multiple cysteine-
rich pseudo-repeats) in the extracellular space, but can also be found in a
soluble form in the serum, similar to the TNF receptors, which can either
be type I membrane proteins or a soluble form as decoy receptors [57] [58].
Figure 2.12: CD137L homotrimeric structure and the interaction between
the 3 monomers [57]
Interestingly, the signalling between CD137 and its ligand CD137L is bidi-
rectional, meaning that the binding of CD137 to CD137L is able to induce
regulatory signals in both participants of this contact, and is not limited to
immune cells, such as the monocyte linage, or B- and T-cells, but can also
affect bone marrow cells as well as carcinoma cell lines [56]. Members of the
TNF family generally form trimeric structures, as shown in fig. 5.22, but
can be further divided into three major groups (regarding their final shape).
Group 1 TNFs form bell-shaped trimeric structures, while group 2, due to
disulfide bridges, assumes a more globular shape. The third group is basi-
cally defined by their lack of sequence homologies with the other members
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of the TNF super family. CD137L falls into the last category (Group 3) and
shares this group with CD27, CD30L, OX40L and GITRL [57]. The clini-
cal importance of this receptor - ligand duality lies in the fact that T- and
B-cell lymphomas in patients with leukemia seem to express both, CD137
and the ligand CD137L, which prolongs their survival and helps to induce
proliferation [59]
2.6 CD200 (OX2, MOX1/2):
CD200 (formerly known as OX2) is a type I transmembrane glycoprotein
of 45kDa with two extracellular Ig-like domains, a single transmembrane
region and a short cytoplasmic tail lacking any known domains or motifs.
It is part of the immunoglobulin supergene family, related to a family of
co-stimulatory receptors, called B7 [60], and it is found at the 3q13.2 locus
on chromosome 3. Many different cell types express CD200 on their sur-
face including activated (but not resting) T-cells, thymocytes, ovarian cells,
trophoblasts, dendritic cells, resting B-cells, neurons, endothelial cells and
epithelial cells [61]. CD200 presumably has four interaction partners termed
CD200R1, -R2, -R3 and -R4, of which CD200R1 is the only one confirmed
and seems to be restricted to monocytes, macrophages and dendritic cell
linages, as well as mast cells, basophil cells and certain T-cells. Especially
the binding of CD200 to CD200R1 seems to have a grave impact on the mod-
ulation of the immune system, since studies show that CD200−/− mice are
far more likely to develop autoimmune defects such as spontaneous fetal loss,
graft rejection, inflammatory disorders etc. The reason for this is thought
to lie in the fact that the cytoplasmic part of CD200R1 is equipped with a
NPXY motif, and is therefore able to deliver immunoinhibitory signals [62].
The circumstance that almost only tissues that usually carry CD200 on the
surface are affected by this immune frenzy supports that thesis. CD200 -
CD200R1 cooperation in general is thought to be one of the future „hot
spots“ for the understanding of autoimmune diseases and immune modula-
tion [61].
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2.7 αPak (Pak1):
PAK I (p21-activated kinases) is a family of serin/threonin kinases, which
consists of three isoforms (Pak 1-3), all of which are associated with the GT-
Pases Rac and Cdc42. Pak1 (αPak, p68), Pak2 (βPak, p65) and Pak3 (γPak,
p62) are a evolutionary highly conserved group of kinases with dozens of sub-
strates, and are therefore consolidated under the term PAK I, to distinguish
them from their less cognate relatives, the PAK II kinases. PAK I kinases
share a common structure and are characterized by an N-terminal regulatory
domain, harboring a p21 GTPase binding domain (PBD), a CRIB region (for
Cdc42 and Rac interactive binding), together with a partially overlapping
autoinhibitory domain (AID), followed by proline rich regions, which serve as
binding sites for proteins with SH3-domains. Within the PAK I family, the
Figure 2.13: Schematic diagram indicating features of PAK1 structure with
p21 GTPase binding, autoinhibitory (AI) and catalytic domains. [63]
regulatory domains differ from each other through the number of canonical
PXXP SH3-binding motifs (five in Pak1, two in Pak2 and four in Pak3) and
a nonclassical (PXP) SH3-binding site [63]. The first binding site in Pak1
is interacting with Nck, an SH2-SH3 adaptor protein, which links the kinase
to receptor tyrosine kinases via its SH2 domain [64]. Using Nck, Pak1 can
also interact via its PXXP motifs. The C-terminal part hosts the catalytic
(kinase) domain, which can be found in different variants, due to alternative
splicing of the Pak mRNA. There are two different splice variants of Pak1
known in man (Pak1 and Pak1B), and several splice forms of the Pak3 C-
terminus, which are usually highly expressed in neurons. The expression of
Pak kinases in leukocytes is restricted to Pak1 and Pak2. In white blood
cells (neutrophils, macrophages, mast cells and T-cells) these kinases play
an important role in the reorganization of the cytoskeleton, and their ability
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to activate the Erk pathway as well as their role in other cellular processes
such as cell motility, apoptosis, mitosis, and transcription, underscores their
importance in the immune-response [65]. The activation of the NFAT and
Erk pathway (see Fig 2.14) via the T-cell receptor relies on Pak1 functionally
located downstream of a Nck/Vav/SLP-76 signalling complex [66]. PAKs are
usually overexpressed and/or hyperactivated in tumor tissue, which means
that their role in cell transformation makes them an attractive target for the
development of tumor specific therapies. [67] When not activated via a GT-
Figure 2.14: The role of PAKs in the activation of immune-relevant pathways
[67]
Pase, PAKs form homodimers, which keeps them in their conformationally
restricted, inactive state, in which the inhibitory switch domain covers the
catalytic domain, thus rendering it catalytically incompetent. Upon activa-
tion, a conformational change is induced, due to the binding of an active
GTPase to the N-terminal p21 binding domain (PBD). Activation through
a GTPase occurs by binding of Rac1, Rac2, Rac3, Cdc42, but also by CHP,
TC10 and Wrch-1 to the p21 binding domain, but does not occur when
interacting with Rho A-G or other members of the Ras superfamily [63].
This unfolding event allows the autoinhibitory domain to dissociate from
the catalytic domain, which leads to autophosphorylation in both the kinase
domain, at Thr423 in the activation loop, and at the regulatory domain sit-
uated at the N-terminus. The autophosphorylation of Thr423 seems to play
an important role in the final activation steps, since it helps to maintain relief
from autoihibition and thus promotes further substrate phosphorylation [65].
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2.8 Nck:
Nck (non-catalytic region of tyrosine kinase) is a family of cytosolic adapter
proteins with a relative molecular mass of 47kDa, which consist of one C-
localized SH2 domain, and three SH3 domains connected with linker regions
(Figure 2.15). In other words, they could potentially interact with three
different downstream or upstream proteins. There are 2 known members
of the Nck family in humans, namely Nck1/Nckα and Nck2/Nckβ or Grb4,
two known members in mice, which are called mNckα and mNckβ and one
known relative in drosophila (Dock) [68]. In humans the gene coding for
Nck1 is localized to the 3q21 locus of chromosome 3, the gene for Nck2 is
found on chromosome 2 at the 2q12 locus. These two genes however produce
two Nck molecules, which are identical in 68% of their amino acid sequence,
with most differences in the linker regions. The similarity between the two
Ncks leads to some extent to a functional redundancy, although their ex-
pression pattern varies within different tissues. Nevertheless, neither Nck1
nor Nck2 knock-out mice showed any phenotype change, although double
knock-outs are fatal in utero due to problems with structures derived from
mesodermic tissue, indicating that Nck must have a vital part in mammalian
development [69].
Figure 2.15: Domain-homology between Nck1 and Nck2 in percent [12]
There are, however, studies which have shown that there might be dis-
tinct functions for both isoforms, since the regulation of the actin cytoskele-
ton in fibroblasts and breast carcinomas depends on signalling of platelet-
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derived growth factor (PDGF) and epidermal growth factor (EGF) via Nck2
(exclusively) [70]. Furthermore, the control neuritogenesis seems to be re-
lated to the function of Nck2 [12]. The importance of Nck proteins is further
Figure 2.16: Nck in T-cell signalling [12]
illustrated by their role in T-cell signalling, since they link receptor tyrosine
kinases (RTKs) with the actin cytoskeleton remodeling machinery, which was
demonstrated by co-localization and biochemical studies, indicating that Nck
forms a multi protein complex with Vav and SLP-76 (see Figure 2.16) [68].
Additionally, Roy et al showed that Nck knock-out leads to severe T-cell
lymphopenia in mice which expressed a transgenic TCR receptor. Thus Nck
seems to play a crucial role in the orchestration and modulation of TCR
signalling in response to foreign and self antigen stimulation [69].
Another important point is the interaction between Nck and Pak. Recently,
new interaction partners were identified: Pix for „Pak interacting exchange
factors“, also termed Cool for „cloned out of library“. αPix (Cool-1) and
βPix (Cool-2) and are both equipped with a SH3 domain, a PH domain and
a Dbl-homology (DH) domain [68]. Pak is probably recruited to the plasma
membrane by Nck and binds to autophosphorylated receptor tyrosine kinases
using its SH2 domain. The N-terminal first proline-rich region of Pak binds
to Nck’s SH3 domain [12], whereas Pix uses different proline-rich regions
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of Pak to bind via its SH3 domain, situated C-terminal of the p21-binding
domain (PBD). Studies show that the interaction between Nck and Pak is
increased during adhesion or cell-cell contact, and is reduced again after the
loss of contact. Since Pak and Pix are recruited to receptor tyrosine kinases
via Nck, and Pix can localize Pak to focal complexes, it is likely that the
Nck/Pak/Pix complex is responsible for recruiting receptor tyrosine kinases
to focal complexes [68].
2.9 Aim of this study:
As mentioned above, the role of CD2 as a co-stimulatory molecule in T-cell
activation and anergy is not fully understood yet. We therefore conducted
experiments to identify genes and proteins affected by αCD2-stimulation in
the context of a CD4+ helper T-cell poulation. A series of previous TaqMAN
assays with the goal to confirm genes showing elevated mRNA expression
following CD2 stimulation revealed a handful of genes with significantly in-
creased mRNA levels. We picked four candidate genes to further investigate
their protein expression pattern over a time period of 72 hours.
Nck was picked due to its nature as a SH2/SH3 adaptor protein, which has
already been shown to interact with the cytosolic tail of CD2 (the proline
rich sequences to be exact). Since it is thought to recruit kinases such as
αPak to the cell membrane, Nck is a valuable target to further investigate
downstream targets of CD2 signalling.
αPak seemed to be an interesting target since as a kinase, involved in many
cellular processes, it is a main hub for different pathways. The elevated
mRNA levels might be an indication for its direct or indirect involvement in
CD2 signalling.
As for CD137L, current literature proposes that this ligand is restricted to
the myeloid linage and is only expressed in exceptional cases on members
of the lymphoid linage (T and B-cell lymphomas), it was interesting to find
elevated levels of CD137L mRNA in CD2 stimulated T-helper-cells. There-
fore we chose to include this protein in our survey to further illume this
circumstance, since a positive result would bring new light into the regula-
tory functions of T-effector cells.
OX2 / CD200 also showed increased levels of mRNA in the TaqMAN as-
says, and was picked for a similar reason as CD137L. It is thought that
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CD200 plays a role in T-cell anergy and autoimmune reactions. We therefore
suggested that CD2 might be connected to T-cell anergy and self-tolerance
amongst others through CD200 and/or CD137L. In this study we tried to in-
vestigate a correlation between the results of the TaqMAN assays regarding
the mRNA concentration and the actual protein product in CD4+/HLADR-
/CD25- Th-cell populations.
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Materials and Methods
3.1 Stock solutions
10% Sodium Dodecyl Sulfate (SDS)
Dissolve 10 g of electrophoresis-grade SDS (MW = 288.37 g/mol) in 80 ml of
distilled H20. Add distilled H20 to make a total volume of 100 ml of solution.
Store at room temperature (indefinitely).
1.5 M Tris (pH 8.8)
Dissolve 181.5 g of Tris base (MW = 121.14 g/mol) in 800 ml of double dis-
tilled H20. Adjust the pH to 8.8 with concentrated HCl. Adjust the volume
to 1 L. Aliquote in convenient volumes. Store at room temperature.
1.0 M Tris (pH 7.3)
Dissolve 12.1 g of Tris base (MW = 121.14 g/mol) in 80 ml of double distilled
H20. Adjust the pH to 7.3 with concentrated HCl. Adjust the volume to 100
ml. Store at room temperature.
1.0 M Tris (pH 6.8)
Dissolve 12.1 g of Tris base (MW = 121.14 g/mol) in 80 ml of double distilled
H20. Adjust the pH to 6.8 with concentrated HCl. Adjust the volume to 100
ml. Store at room temperature.
5 M NaCl (500 ml)
Dissolve 146.1 g of NaCl (MW = 58.44 g/mol) in 450 ml of distilled H20.
Adjust the volume to 500 ml. Store at room temperature.
Phenylmethylsulfonyl Fluoride (PMSF)
Also called α-toluenesulfonyl chloride, PMSF (MW = 174.19 g/mol) is used
as an inhibitor of serine proteases. It is very toxic. Aqueous solutions of
PMSF are hydrolyzed very rapidly. Make a 100 mM stock solution (i.e.
174 mg/10 ml) in absolute ethanol or 2-propanol. Aliquot and store in foil
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wrapped tubes at -20°C. Add to aqueous solutions immediately before use.
Caution: PMSF is inactivated in aqueous solutions. The rate of inacti-
vation increases with pH and is faster at 25°C than at 4°C. The half-life of a
20µm aqueous solution of PMSF is about 35 times shorter at pH 8.0. Thus
aqueous solutions of PMSF can be safely discarded at a higher pH than 8.6
and storing for several hours at room temperature. [Lab Ref. Volume 2 ]
10% Ammonium Persulfate (APS)
Dissolve 0.1 g in 1 ml of double distilled H2O. Mix by vortexing.
Ponceau S
Dissolve 2 g of Ponceau S, 30 g of trichloracetic acid, and 30 g of sulfonsali-
cylic acid in 100 ml of distilled H2O.
TBS + 0.25% Tween + 0.25% TritonX (TBST+T)
– 1 M Tris (pH 7.3) 10 ml (10mM)
– 5 M NaCl (MW = 58.44 g/mol) 20 ml (100mM)
– Tween 20 0,5 ml (0.05%)
– Triton X 0,5 ml (0.05%)
Adjust the volume to 1 L with double distilled H2O. Store at room temper-
ature.
10x Phosphate Buffered Saline (PBS) (ph 7.2-7.4)
– 137 mM NaCl (MW = 58.44 g/mol) 8 g
– 2.7 mM KCl (MW= 74.55 g/mol) 200 mg
– 10 mM Na2HPO4 (MW= 141.96 g/mol) 1.44 g
– 2 mM KH2PO4 (MW= 136.09 g/mol) 240 mg
Dissolve components in approximately 0.9 liter of double distilled H2O. Ad-
just the pH to 7.2 - 7.4 with concentrated HCl and adjust the final volume
to 1 L with double distilled H2O. Store at room temperature.
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5x Tris Buffered Saline (TBS) (ph 7.15)
– 1 M Tris-HCl (pH 7.3) 50 ml
– 5 M NaCl (MW = 58.44 g/mol) 150 ml
Dilute components in 1 L of double distilled H2O.
Lysis buffer II
– Triton X 10%, 10x TBS 1 ml
– PMSF 100mM 100 µl
– Phosphatase Inhibitor Cocktail (Sigma) 100 µl
– Protease Inhibitor Cocktail (Sigma) 100 µl
– double distilled H2O to make 10 ml
10x Running Buffer (1 L)
– 250 mM Tris base (MW = 121.14 g/mol) 30.3 g
– 2 M glycine (MW= 75.7 g/mol) 150 g
– 1% SDS (MW = 288.38.14 g/mol) 10 g
– double distilled H2O to make 1 L
10x Western Transfer Buffer (10 L)
– 25 mM Tris base (MW = 121.14 g/mol) 30.3 g
– 0.2 M glycine (MW= 75.7 g/mol) 150 g
– MeOH 20% 2 L
– add distilled H2O 80% to make 10 L
Sample Buffer II
– 2 M glycerol (MW = 92.10) 2 ml
– 1 M Tris pH 6.8 1.25 ml
– 20% SDS (MW = 288.38.14 g/mol) 1 ml
– bromophenol blue 1,6 mg
– adjust the final volume to 10 ml with double distilled H2O.
– always add 5% β-mercapto EtOH right before use
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Stripping Solution (pH 6.7)
– 100 mM β-mercapto EtOH 142 µl
– 2% SDS (MW = 288.38.14 g/mol) 4 g
– Tris/HCl (MW = 157.59 g/mol) 1.51 g
– dissolve SDS and Tris/HCl in 180 ml H2O
– adjust pH to 6.7 with NaOH
– always add β-mercapto EtOH right before use
3.2 Isolation of Mononuclear Cells (MNCs)
Peripheral blood was drawn from healthy volunteers. The study was con-
ducted according to the mandatory ethical regulations posed by the bioethic
commission of the Medical University of Vienna.
– Collect blood from a volunteer in vacuette EDTA tubes
– Dilute blood with PBS 1:3
– Dispense 15 ml of Ficoll® into 50 ml Falcon tubes, and carefully overlay
with 35 ml of blood-PBS dilution. The blood phase and the Ficoll phase
must not get mixed
– Centrifuge the tubes at 1400 rpm for 40 min at room temperature. Set the
breaks of the centrifuge to 0.
– Discard the plasma phase and pool the MNC fraction in a new 50 ml Falcon
tube (See Fig.: 3.1)
– Adjust the volume of the MNC suspension to 50 ml with sterile PBS
– Centrifuge at 1200 rpm for 10 min at 4°C with breaks enabled
– Discard the supernatant (without disturbing the pellet!), resuspend the
pellet in the remaining few µl and add 25 ml of sterile PBS to wash the cells.
– Centrifuge at 800 rpm for 10 min at 4°C with breaks enabled
– Discard the supernatant (without disturbing the pellet!), resuspend the
pellet in the remaining few µl and add 10 ml of RPMI medium.
– Count Cells.
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Figure 3.1: On the left: (top down) Blood-PBS (B), Ficoll® (F). On the
right: (top down) Plasma (P), MNC layer (W), Ficoll®, red blood cells and
granulocytes (R)
3.3 Isolation of CD4+ cells
CD4 positive T-helper cells are negatively sorted with DYNAL® Magnetic
Beads using specific antibodies (table: 3.2) and DYNAL® Magnetic Beads
coated with sheep anti-mouse IgG antibodies.
– Wash beads to remove preservatives
– Estimate the number of cells to be depleted
– Calculate 4 beads per cell to be depleted and transfer the corresponding
volume of beads into a sterile eppendorf 1,5 ml tube
– Place the tube next to the magnet and let it rest for 5 min
– Discard the liquid (carefully!)
– Remove the tube from the magnet
– Add PBS and resuspend the beads
– Put the tube back on the magnet and let it rest again for 5 min
– Repeat the PBS washing step two times
– Resuspend the beads in an adequate volume of PBS or RPMI medium
– Resuspend the MNCs at 2 x 107 cells per ml of RPMI medium
– Add the following antibodies (at the concentration indicated in Table 3.2)
for depletion
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Table 3.1: Antibodies used for sorting and their dilution (for concentration
see: 7.2 References)
dilution target cell
CD8 1:200 cytotoxic lymphocytes
CD13 1:200 myelomonocytic cells
CD14 1:100 myelomonocytic cells
CD16 1:100 neutrophils, NK-cells, macrophages
CD19 1:200 B-cells
CD25 1:200 activated T-cells, Treg, B-cells, monocytes
CD235a 1:200 erythrocytes
HLA-DR 1:200 activated T-cells, B-cells, monocytes
TCRγδ 1:200 subpopulation of T cells
– Rotate for 30 min at 4°C
– Spin the cells at 1200 rpm, 4°C for 10 min
– Discard the supernatant and resuspend again in RPMI medium
– Add the dynabeads and gently rotate for 30 minutes (maximum 60 min!)
at 4°C
– Place the tube next to the magnet and let it rest for 5 min
– Carefully transfer the cell suspension into a new tube (without touching
the bead-pellet!)
– Put the new tube with the cells again onto the bead magnet and let it rest
for 5 min
– Repeat the last two steps to eliminate all remaining beads from the cell
suspension
– Count remaining cells.
– Check the purity of the cell population via fluorescence activated cell sorting
(FACS) (see following chapter)
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3.4 FACS - Analysis
After the sorting step, check the purity of the resting CD4+ population via
FACS using aliquotes of the cell suspension in order to detect contamination
with other cell types.
– for each celltype (MNC / T-cell) aliquot 200.000 cells into a FACS tube.
– (MNC only!): add 30 µl of human IgG (1 mg/ml - Sigma-Aldrich)
– let MNC / IgG incubate on ice for 10 min
– add FITC and PE labelled antibodies (as indicated in Table 3.2) to MNC
and T-cells
Table 3.2: FACS-Antibody dilutions
MNC Tcell FITC PE Dilution
1 14 FITC Co - 1:20
2 15 - PE Co 1:20
3 16 CD3 - 1:20
4 17 - CD3 1:20
5 18 CD2 CD3 1:20
6 19 CD4 CD3 1:20
7 20 CD8 CD3 1:20
8 21 CD3 CD14 1:20
9 22 CD3 CD16 1:20
10 23 CD3 CD19 1:20
11 24 CD3 CD25 1:20
12 25 CD3 HLA-DR 1:20
13 26 CD3 TCRγδ 1:20
– incubate the cells with the antibodies for 30 min at 4°C in the dark
– add 250 µl of PBS and spin at 3000 rpm for 10 min at 4°C
– discard the supernatant and resuspend the pellet in 500 µl PBS (vortex)
– spin at 3000 rpm for 10 min at 4°C
– discard the supernatant and resuspend the pellet in 500 µl PBS (vortex)
– spin at 3000 rpm for 10 min at 4°C
– discard the supernatant and resuspend the pellet in 500 µl PBS (vortex)
– FACS Analysis
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3.5 Cell Culture
Purified CD4+ cells were distributed into 3x3 wells, at 5x106 cells per 3 ml
medium per well. Three timepoints (24h, 48h, 72h) with one negative control
(no stimulation), CD2 stimulation and CD3 control stimulation each, hence
the 3x3 wells. Incubation at 37°C in a humidified atmosphere containing 5%
CO2
l0.4
Figure 3.2: Black: 24h / Red: 48h / Blue: 72h
CD2 stimulation:
Two antibodies directed against different epitopes (T112 and T113) of CD2
were used in order to maximize the stimulation. (See 3.7 for detailed anti-
body description and concentration)
– aliquot 5x106 cells resuspended in 3 ml RPMI medium into each CD2 well
– add 5 µg/ml of Vit13 antibody -> 12 µl
– add 5 µg/ml of 6F10.3 antibody -> 75 µl
– incubate for 24, 48 and 72 hours
– after each timepoint harvest and lyse the cells in lysisbuffer II (see chapter
3.6)
CD3 stimulation:
(See 3.7 for detailed antibody description and concentration)
– dilute 5 µg/ml of OKT3 (CD3) -> 5 µl antibody with 995 µl of 37°C PBS
for each CD3 well
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– pipet 1 ml of the OKT3 dilution into each CD3 well
– incubate for 30 min at 37°C
– discard the supernatant and wash 3 times with 37°C PBS
– add 5x106 cells resuspended in 3 ml medium into each CD3 well
– incubate for 24, 48 and 72 hours and lyse the harvested cells
3.6 Harvesting
For each timepoint:
– transfer the cell suspension from each well into new 15 ml Falcon tubes.
– wash the well 3x with PBS and transfer the suspension into the Falcon tube
– count cells
– branch off 1.600.000 cells for further FACS stainings (see 3.3) into a new
Falcon (200.000 for each staning)
– spin the remaining cells at 1200 rpm, 4°C
– discard the supernatant and resuspend the cell pellet in lysis-buffer II (2x107
cells per ml lysis buffer)
– lyse 1 h on ice, then spin the lysate at 15000 rpm at 4°C for 10 min and
transfer the supernatant into a new eppendorf 1.5 ml tube. Store lysate at
-20°C
Check stimulation via FACS using the surface expression of specific activa-
tion associated surface molecules (CD69, CD25 and HLA-DR):
add FITC and PE labeled antibodies (as indicated in Tables 3.3 and 3.4) to
the T-cell vials
– incubate the cells with the antibodies for 30 min at 4°C in the dark.
– add 250 µl of PBS and spin at 3000 rpm for 10 min at 4°C
– discard the supernatant and resuspend the pellet in 500 µl PBS (vortex)
– spin at 3000 rpm for 10 min at 4°C
– discard the supernatant and resuspend the pellet in 500 µl PBS (vortex)
– spin at 3000 rpm for 10 min at 4°C
– discard the supernatant and resuspend the pellet in 500 µl PBS (vortex)
– FACS analysis
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Table 3.3: FACS scheme for unstimulated and CD2 stimulated T-cells:
T-cell FITC PE Dilution
1 FITC Co - 1:20
2 - PE Co 1:20
3 CD3 - 1:20
4 - CD3 1:20
5 CD2 CD3 1:20
6 CD3 CD69 1:20
7 CD3 CD25 1:20
8 CD3 HLA-DR 1:20
Table 3.4: FACS scheme for CD3 stimulated T-cells:
T-cell FITC PE Dilution
1 FITC Co - 1:20
2 - PE Co 1:20
3 CD3 - 1:20
4 - CD3 1:20
5 CD2 CD3 1:20
6 CD2 CD69 1:20
7 CD2 CD25 1:20
8 CD2 HLA-DR 1:20
3.7 IP / Western Blot
For proteins with a low concentration in the cell lysate, immunoprecipitations
were performed to enrich the target molecule.
3.7.1 Immunoprecipitation
– mix 30 µl of Protein G Plus-Agarose suspension (Calbiochem®) with 5 µl
of antibody (final concentration 1:100 with 500 µl of cell lysate)
– incubate at 4°C for 15-30 min
– add 500 µl of cell- lysate
– rotate for one hour at 4°C
– spin the samples at 3000 rpm for 5 min
– discard the supernatant
– wash with 500 µl lysisbuffer II (undiluted)
3.7. IP / WESTERN BLOT 45
– spin the samples at 3000 rpm for 5 min
– discard the supernatant
– wash again with 500 µl lysisbuffer II (undiluted)
– spin the samples at 3000 rpm for 5 min
– discard the supernatant
– wash with 500 µl lysisbuffer II (diluted 1:10 with TBS)
– spin the samples at 3000 rpm for 5 min
– discard the supernatant
– add 35 µl of Sample Buffer II
3.7.2 Polyacrylamide Gel elektrophoresis (PAGE)
Hand-casted polyacrylamide gels were used to separate the different proteins
in the cell lysate and in the immuno-precipitates according to their molecular
weight.
– 9% Resolving Gel (10 ml for 2 gels):
∗ double distilled H2O 4.3 ml
∗ 30% acrylamide mix 3.0 ml
∗ 1,5 M Tris (pH 8.8) 2.5 ml
∗ 10% SDS 100 µl
∗ 10% APS 100 µl
∗ TEMED 6 µl
∗ overlay with H2O
∗ let polymerize (aprox. 20 min)
∗ discard the remaining water before continuing
– 5% Stacking Gel (3 ml for 2 Gels)
∗ distilled H2O 2.1 ml
∗ 30% acrylamide mix 0.5 ml
∗ 1 M Tris (pH 6.8) 380 µl
∗ 10% SDS 30 µl
∗ 10% APS 30 µl
∗ TEMED 3 µl
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∗ let polymerize (aprox. 20 minutes)
– add 20 µl Sample Buffer II to 20 µl sample (cell lysate or precipitate)
– boil sample at 95°C for 5 min
– load the gel, and let it run for 120 min at 120 V or until the dye front
reaches the bottom of the gel
3.7.3 Western blot
After separation via PAGE, the proteins were transferred to a nitrocellulose
membrane, which was then incubated with specific antibodies to detect the
four target molecules.
– Assemble the sandwich blot (Mini-PROTEAN by Biorad®) in a bowl filled
with transfer buffer in the following order:
1) open a blotting cassette (black side at the bottom)
2) soaked sponge
3) 2-3 layers of soaked 3M blotting paper
4) PAGE gel (see 3.7.2)
5) soaked nitrocellulose membrane (Amersham Hybond ECL)
5) 2-3 layers of 3M blotting paper
use a 10 ml pipett to carefully remove any air bubbles that might sit between
the gel and the membrane
6) soaked sponge
close and secure the sandwich cassette
– place the cassettes into the Western transfer tank (Mini-PROTEAN by
Biorad®)
– fill the tank with Western transfer buffer
– let it run for 90 min at 100 V
– after Western transfer, wash twice with TBST and immerse the membrane
in a sufficient amount of Ponceau staining solution and stain for 5 min (do
this before blocking!) The total transfered proteins should be visible now.
– after staining, transfer the membrane into water for two washes of 5 minutes
each.
– wash with TBST+T (few seconds) until the ponceau stain is fully removed.
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– block non-specific binding sites on the membrane with 5% non-fat dried
milk in TBST (blocking solution) for 1 h at room temperature on an orbital
shaker.
– wash 2x with TBST+T for 15 min
– add primary antibody (diluted according to Table 3.9) in 3 ml TBST+T
with 5% non-fat dried milk and incubate over night at 4°C.
– wash 3x with TBST for 20 min
– add secondary (HRP conjugated) antibody (according to Table 3.9 1:4000)
and incubate for 1 h
– wash 3x with TBST+T for 20 min
3.7.4 Stripping for reprobing
Blots may be stripped for the de novo incubation with a different primary
antibody.
– place the membrane with the protein side facing up into the stripping so-
lution (+fresh β-Mercapto EtOH)
– incubate at 50°C for 30 min (shake from time to time)
– wash with TBST+T 2x for a few seconds, 3x for 20 minutes
– block the stripped membrane again for 1 h with non fat dry milk (see 3.7.3
for details)
– incubate with new antibody (e.g. α-beta-actin) over night
3.7.5 Detection / ECL
The acronym ECL stands for Enhanced Chemical Luminiscence, and is a
non-radioactive method for protein detection on Western blots. It is based
on a chemical reaction between the ECL solution and the secondary an-
tibody which is conjugated to horseradish peroxidase (HRP). While most
ECL reactions oxidize the cyclic diacylhydrazide luminol, we used an ECL
solution that is based on the enzymatic generation of an acridinium ester,
which produces a more intense light emission of longer duration (ECL+ GE
Healthcare®). Combined HRP and peroxide catalyzed oxidation of the Lu-
migen PS-3 Acridan substrate generates thousands of acridinium ester inter-
mediates per minute. These intermediates react with peroxide under slight
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alkaline conditions to produce a sustained, high intensity chemiluminescence
with maximum emission at a wavelength of 430 nm (see Figure: 3.3). The
resulting light is detected on autoradiography film (Hyperfilm ECL from GE
Healthcare®).
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3.8 Reagents:
Greiner Bio-One:
VACUETTE EDTA Tubes
Cat. No. 455226
Greiner Bio-One GmbH Bad Haller Straße 32 A-4550 Kremsmünster Öster-
reich
Calbiochem:
Protein G Plus-Agarose Suspension
Cat. No. IP04
EMD Chemicals, Inc. 480 S. Democrat Road 08027 Gibbstown United States
Invitrogen:
Dynabeads® Sheep-anti Mouse IgG
Cat. No. 110-31
Invitrogen Corporation, 1600 Faraday Avenue, Carlsbad, California 92008.
GE Healthcare:
Ficoll-Paque PLUS
Cat. No. 17-1440-03
Amersham Hybond ECL Membrane
Cat. No. RPN203D
Amersham Hyperfilm ECL
Cat. No. 28-9068-36
ECL Western Blotting Detection Reagents
Cat. No. RPN2109
GE Healthcare Europe GmbH Zweigniederlassung Österreich Euro Plaza,
Building E Wienerbergstrasse 41 A-1120 Wien Austria
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PAA:
RPMI 1640 Ready Mix
Cat. No. R15-802
Dulbecco’s PBS for Cell Culture
Cat. No. H15-002
PAA Laboratories GmbH PAA-Strasse 1 4061 Pasching Austria
Sigma-Aldrich:
IgG from human serum
Cat. No. I4506
GSigma-Aldrich Corporate Offices Sigma-Aldrich 3050 Spruce St. St. Louis,
MO 63103, USA
3.9 Equipment:
Biorad:
PAGE: Mini-PROTEAN Electrophoresis System
Western transfer: Mini Trans-Blot Cell
Bio-Rad Laboratories, Inc. 1000 Alfred Nobel Drive Hercules, CA 94547
USA
Becton Dickson (BD):
FACS: BD FACS Calibur Flow Cytometer
Immunocytometry Systems Pharmingen 2350 Qume Drive San Jose, CA,
USA 95131
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3.10 Antibodies
Becton Dickson (BD):
Immunocytometry Systems Pharmingen
2350 Qume Drive
San Jose, CA, USA 95131
Santa Cruz Biotechnology:
Santa Cruz Biotechnology, INC.: International Headquarters Santa Cruz
Biotechnology, Inc. 2145 Delaware Avenue Santa Cruz, California 95060
U.S.A.
Beckman Coulter:
Worldwide Headquarters: Beckan Coulter, Inc.: 250 S. Kraemer Boulevard,
P.O. Box 8000 Brea, CA 92822-8000 USA
Antibodies for sorting
Antibody Concentration Company # Clone
CD8 0.2 mg/ml BeckmanCoulter IM0102 B9.11
CD13 0.2 mg/ml BeckmanCoulter IM0713 SJ1D1
CD14 0.2 mg/ml BeckmanCoulter IM0643 RMO52
CD16 0.2 mg/ml BeckmanCoulter IM0813 3G8
CD19 0.2 mg/ml BeckmanCoulter IM1313 J3-119
CD25 0.2 mg/ml BeckmanCoulter 0119 B1.49.9
CD235a 0.2 mg/ml BeckmanCoulter IM2210 11E4B
TCRγδ 0.1 mg/ml BeckmanCoulter IM1313 IMMU510
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Table 3.5: FACS Antibodies
Antibody FITC/PE Company # Clone
CD2 FITC BD 555326 RPA-2.10
CD3 FITC BD 555339 HIT3a
CD4 PE BD 340419 L120
CD8 PE BeckmanCoulter IM0452 B9.11
CD14 PE BeckmanCoulter A07764 RMO52
CD16 PE BeckmanCoulter IM1238 3G8
CD19 PE BeckmanCoulter IM1285 J3-119
CD25 PE BeckmanCoulter IM0479 B1.49.9
CD69 PE BeckmanCoulter IM1943 TP1.55.3
HLA-DR PE BeckmanCoulter IM1639 Immu-357
TCRγδ PE BeckmanCoulter IM1418 IMMU510
Table 3.6: Antibodies for stimulation
Antibody Concentration Target Isotype Clone
CD2 (6F10.3) 5 µg/ml T11.2 epitope IgG1 6F10.3
CD2 (Vit13) 5 µg/ml T11.3 epitope IgG1 Vit13
CD3 (OKT3) 5 µg/ml CD3 /γ IgG2a OKT3
Table 3.7: 6F10.3:Immunotech (Marseille, France); Vit13: mAb Vit13 was
kindly provided by O. Majdic (Institute of Immunology - Medical University
of Vienna)
Table 3.8: Primary Antibodies for Western Blot
Antibody Manufacturer Dilution factor #
αPAK (C-19) Santa Cruz 1:400 sc-881
NCK 1/2 (C-19) Santa Cruz 1:400 sc-290
OX2 (R-17) Santa Cruz 1:300 sc-14388
CD137L (C-20) Santa Cruz 1:300 sc-11817
Table 3.9: Secondary Antibodies
Antibody Manufacturer Dilution factor #
ECL Rabbit IgG (HRP) GE Healthcare 1:4000 NA9310-1ML
ECL Mouse IgG (HRP) GE Healthcare 1:4000 NXA931-1ML
ECL Goat IgG (HRP) GE Healthcare 1:4000 NA935
Preliminary mRNA Data
The mRNA data we used to select our target proteins was acquired in our
lab before we started this project. For this, anti-CD2 and anti-CD3 stimu-
lated Cd4+ / CD25- / HLA-DR- cells were lysed, and their gene expression
investigated via an Affymetrix© Genotyping chip. Genes that showed an
increased mRNA transcription were further examined by reverse transcribing
their mRNA into cDNA, which was then measured with real-time quantita-
tive PCR (TaqMAN), to confirm these findings. In the last step, we listed
genes with a confirmed upregulated mRNA transcription and picked four
proteins which seemed interesting for the context of CD2 signalling, and for
which commercial antibodies for Westernblot detection were available. The
data below shows the mRNA expression levels [Sunder-Plassmann Lab].
Figure 4.1: TaqMAN experiments: NCK mRNA expression of helper-
cells after 2 hours of stimulation with anti-CD2 or anti-CD3 mAb (as well as
unstimulated cells). The expressed mRNA was transcribed into cDNA and
measured with a Real time quantitative PCR (TaqMAN). The „signal value“
represents the measured fluorescence, which was emitted in direct correlation
to the initial amount of cDNA, and was normalized to an eukaryotic 18S
rRNA endogenous control (Applied Biosystems)
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Figure 4.2: TaqMAN experiments: αPak mRNA expression of helper-
cells after 2 hours of stimulation with anti-CD2 or anti-CD3 mAb (as well as
unstimulated cells). The expressed mRNA was transcribed into cDNA and
measured with a Real time quantitative PCR (TaqMAN). The „signal value“
represents the measured fluorescence, which was emitted in direct correlation
to the initial amount of cDNA, and was normalized to an eukaryotic 18S
rRNA endogenous control (Applied Biosystems)
Figure 4.3: TaqMAN experiments: CD137L mRNA expression of helper-
cells after 2 hours of stimulation with anti-CD2 or anti-CD3 mAb (as well as
unstimulated cells). The expressed mRNA was transcribed into cDNA and
measured with a Real time quantitative PCR (TaqMAN). The „signal value“
represents the measured fluorescence, which was emitted in direct correlation
to the initial amount of cDNA, and was normalized to an eukaryotic 18S
rRNA endogenous control (Applied Biosystems)
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Figure 4.4: TaqMAN experiments: CD200 mRNA expression of helper-
cells after 2 hours of stimulation with anti-CD2 or anti-CD3 mAb (as well as
unstimulated cells). The expressed mRNA was transcribed into cDNA and
measured with a Real time quantitative PCR (TaqMAN). The „signal value“
represents the measured fluorescence, which was emitted in direct correlation
to the initial amount of cDNA, and was normalized to an eukaryotic 18S
rRNA endogenous control (Applied Biosystems)
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Results
5.1 The impact of CD2 stimulation on Th-cells
Preliminary raised data from our lab indicated an increased mRNA expres-
sion of several genes in purified CD4+/ CD25- / HLADR- T-helper-cells
after CD2 stimulation. We suggested a direct or indirect impact of CD2 on
the transcriptional control of these genes, therefore we decided to pick four
genes (NCK, αPak, CD200, CD137L) which displayed an increased tran-
scription rate, or with an alleged interaction with CD2, and looked at their
protein expression pattern after 24, 48 and 72 hours of stimulation with anti-
CD2 antibodies. Therefore, we stimulated CD4+ / CD25- / HLA-DR- T-cell
populations with αCD2 (6F10.3 + Vit13) to match the mRNA results with
actual protein levels detectable in the cell lysate. We were able to confirm a
potent stimulation of αPak production upon αCD2 stimulation, in contrast
to CD200 which only showed a very feeble signal on the western blot if at
all. The expression pattern of Nck did not change significantly, however we
found an increased expression of CD137L, which in this context, has not
been described in literature before.
5.2 Purified Th-cells
We aimed to work with a highly pure and strictly CD4+ /CD25 - /HLA-
DR- population, to verify the mRNA findings. Therefore, sorting out the
right population was vital for the following procedures. We chose to isolate
the cells manually instead of FACS assisted sorting, because of the stress-
ing nature of the FACS-procedure and a possible biased result due to the
ex ante stress situation. The following FACS results gave us an overview
over the composition of the MNC population (cells from multiple linages)
and the sorted population (purified CD4+ / CD25- / HLA-DR- T-helper
cells). Situated on the left side of the figures is the MNC population, which
is basically a mix of different cell types before sorting, and shown on the
right side is the purified T-cell fraction after depletion of unsolicited cells.
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The tables on the far right side show the percentage of cells in each sector,
according to their staining (UL - upper left / UR - upper right / LL -
lower left / LR - lower right). Both populations were stained with a FITC
(Fluoresceinisothiocyanat) labeled anti human CD3 mAb which served as a
T-cell marker. To identify the various cell types of the MNC fraction and to
check the purity of the T-cell fraction, both were furthermore stained with
PE (Phycoerythrin) labeled mAb directed against cell-type specific surface
markers, mentioned below each figure. These figures show the results of one
representative experiment.
Figure 5.1: CD3 vs CD4 (Th marker)
Figure 5.2: CD3 vs CD8 (Tc marker)
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Figure 5.3: CD3 vs CD14 (monocyte marker)
Figure 5.4: CD3 vs CD16 (neutrophils, and NK-cell marker)
Figure 5.5: CD3 vs CD19 (B-cell marker)
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Figure 5.6: CD3 vs CD25 (activated T-cell marker)
Figure 5.7: CD3 vs HLA-DR (a marker for extended activated T-cell marker)
Figure 5.8: CD3 vs TCRγδ (marker for TCRγδ+ T-cells)
As figure 5.1 shows, there were 16% of CD3-/CD4- (neutrophils, mono-
cytes, eosinophils, NK-cells), 32% of CD3+/CD4- (cytotoxic T-cells), and
about 51% of CD3+/CD4+ (Th) cells in the MNC dotblot (left side), whereas
the sorted cells (right side) showed a CD3+/CD4+, or T-helper-cell purity
rate of almost 99%. CD8 was used to measure the number of cytotoxic T-
cells, and as figure 5.2 indicates, there were 28% cytotoxic T-cells in the
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MNC fraction (left side) with 63% of CD3+/CD8- (T-helper cells or double
negative cells), and 7.23% of unlabeled cells. The T-cell population was free
of Tc cells, since the only CD3+ cells left were CD8-. The next figure (5.3)
shows CD14, as a classic monocyte marker, which was used to assess the
number of myelomonocytic cells in both populations. The figure shows, that
there were around 12% of CD14+/CD3- cells (monocytes) in the MNC frac-
tion (left side), and 0% left in the T-cell population (right side). Figure 5.4
illustrates, that there were 5.8% of CD3-/CD16+/NK cells and neutrophils
in the MNC population (left side), which were also successfully removed
during sorting, due to the fact that only CD3+/CD16- cells remained (right
side). In order to identify B-cell populations (5.5) before, and after sorting,
both fractions were incubated with αCD19 antibodies. The figure illustrates
that there were 6.3% B-cells (CD3-/CD19+) before (left side) and 0% B-
cells (right side) after sorting. Shown in figure 5.6 is CD25, a marker for
activated T-cells, which had to be removed prior to our stimulation exper-
iments, since they would corrupt the results. 4.13% of the population was
CD3+/CD25+ meaning that they were already activated T-cells dwelling
within the MNC population (left side). After sorting, roughly 0.26% re-
mained „CD25+“ (CD25 expression-levels were just above the negative cut-
off). HLA-DR+ cells (Fig 5.7) are committed T-cells and were activated for
a long time, hence representing a biasing problem for the further stimulatio,
just as CD25+ cells do. While the MNC fraction (left side) showed a per-
centage of 5.4 CD3-/HLA-DR+ cells (macrophages, B-cells, dentritic cells)
and 2.7% of CD3+/HLA-DR+ (Th-cells), they vanished almost completely
in the T-cell population after sorting, leaving only around 1% of very low
HLA-DR expressing cells (right side) . Finaly, TCRγδ (Fig 5.8) pose a very
small subpopulation amongst T-cells. The MNC population (left side) con-
tained around 3.2% of TCRγδ+ T-cells, which were reduced after sorting
(right side) to 0.3% which was also just above the negative cut-off.
5.3 T-cell Activation Markers
There are several markers, or surface molecules that are known be expressed
on the surface of activated T-cells. In vitro the classical expression of these
markers is in a clearly defined sequence: CD69, CD25, HLA-DR and last but
not least VLA-1 (not shown). CD69 is usually expressed two to four hours
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after stimulation with an antigen, mitogens or pathogen, since the protein
is usually already produced and stocked, and just has to be transported to
the membrane. CD69 is responsible for the activation of protein tyrosine
kinase and calcium flux activity, as well as the transcription of TNFα and
IL-2 [71]. CD25 takes about 12-24 hours to be expressed on activated T-
cells, whereas HLA-DR takes around 40-60 hours for upregulation and marks
the point after which the immune response moves towards the specific and
adaptive phase [72]. These surface molecules indicate the activation state of
T-cells, and were used to assess the level of activation following stimulation
with anti-CD2 antibodies. After we ensured that the T-cell population was
strictly CD4+ / CD25- / HLA-DR-, we stimulated the populations in vitro in
culture wells via diluted antibodies, either directed against the T11(2) and
T11(3) epitope of CD2 (CD2 stimulation), or against the CD3 /γ chain
(CD3 stimulation). See 3.7 for detailed antibody description.
5.3.1 Stimulation
The two antibodies (6F10.3 + Vit13) were diluted directly into the culture
wells with a concentration of 5µg per ml each. Since the expression of CD2
on the surface decreases after stimulation with αCD2 antibodies, we used
CD3 (FITC) as a general T-cell marker. In contrast to the CD2 stimulation,
the αCD3 antibody (OKT3) was not directly diluted into the RPMI medium,
but was crosslinked to the bottom of the culture-dish well prior to the addi-
tion of the T-cells. This is important, since soluble OKT3 is a highly potent
immunosuppressant and is given to patients after organ transplantations to
reduce acute rejection [73]. In contrast, crosslinked anti-CD3 (OKT3), is in
fact able to do the opposite, videlicet activate resting T-cells [74]. Since stim-
ulation with anti-CD3 antibodies leads to the internalization and therefore
decreased detectability of CD3, we used FITC labeled mAb directed against
CD2 as a T-cell marker in this case.
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CD69: T-cells stimulated with 6F10.3 + Vit13
Figure 5.9: Expression of CD69:
The figure shows the CD69 expression of the helper-cell population
after 24, 48 and 72 hours of stimulation with anti-CD2 (as well as unstim-
ulated cells). CD69 is a C-type lectin protein and is the earliest inducible
surface protein expressed lymphoid cells. It therefore serves as an early
activation marker for T-cells, since it takes only approximately 1-2 hours
from stimulation to presentation of CD69 on the surface of the cell. The
figure illustrates the progression of the stimulation. In the unstimulated
control, about 10% of the displayed Th-cells carry CD69. After 24 hours
of stimulation with anti-CD2 antibodies, it is already a third (31.7%) of all
cells expressing this activation marker, which recedes again after 48 hours
to 21% and returns to 15% after 72 hours of stimulation.
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CD25: T-cells stimulated with 6F10.3 + Vit13
Figure 5.10: Expression of CD25:
The figure shows the CD25 expression of the helper-cell population
after 24, 48 and 72 hours of stimulation with anti-CD2 antibodies (as well
as unstimulated cells). CD25 expression is associated with recent activated
T-cells and is therefore also a marker for the activation status of the T-cell.
It furthermore serves as a high affinity receptor for interleukin 2 (IL-2),
essential for T-cell proliferation). Within the unstimulated population,
there are nearly no (0.08%) CD4+/CD25+ helper cells which only changes
slowly over 24 (0.22%), 48 (0.44%) and 72 (2.32%) hours of stimulation. In
contrast to CD69, CD25 takes longer to be expressed on the surface but is
not downregulated again as CD69 is.
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HLA-DR: T-cells stimulated with 6F10.3 + Vit13
Figure 5.11: Expression of HLA-DR:
The figure shows the HLA-DR expression of the helper-cell popula-
tion after 24, 48 and 72 hours of stimulation anti-CD2 antibodies (as well
as unstimulated cells). HLA-DR is one the human major histocompatibility
complexes, a cell surface receptor encoded by the human leukocyte antigen
complex on chromosome 6, and in context of Th-cells, only expressed on
long term activated T-cells. Unstimulated cells only expressed 1.2% of
HLA-DR, which did not alter much after 24 hours (0.99%) of stimulation.
A slight increase to 1.8% after 48 hours and a final CD3+/HLA-DR+
percentage of 2.3 after 72 hours were measured.
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CD69: T-cells stimulated with crosslinked OKT3
Figure 5.12: Expression of CD69:
The figure shows the CD69 expression of the helper-cell population
after 24, 48 and 72 hours of stimulation with an anti-CD3 antibody (as well
as unstimulated cells). While the unstimulated population already showed
8.82% of CD2+/CD69+ cells, it rapidly increased over 24 hours to 70%,
and continued to rise to 78% after 48 hours with a final percentage of 88%
CD2+/CD69+ helper-cells after 72 hours.
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CD25: T-cells stimulated with crosslinked OKT3
(a)
(b)
Figure 5.13: Expression of CD25:
The figure shows the CD25 expression of the helper-cell population
after 24, 48 and 72 hours of stimulation with an anti-CD3 antibody
(as well as unstimulated cells). About 0,2% of all unstimulated cells
were CD2+/CD25+. Upon stimulation the population shifts to 13% of
CD2+/CD25+ cells, with an increase to 29% after 24 hours and finally
46.2% after 72 hours.
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HLA-DR: T-cells stimulated with crosslinked OKT3
Figure 5.14: Expression of HLA-DR:
The figure shows the HLA-DR expression of the helper-cell popula-
tion after 24, 48 and 72 hours of stimulation with an anti-CD3 antibody (as
well as unstimulated cells). 1.65% of the unstimulated population express
HLA-DR, which increases to 9.1% upon activation of the T-cells with
crosslinked OKT3 after 24 hours. The number further rises to 18% after 48
hours and reaches 25% of CD2+/HLA-DR+ cells after 72 hours.
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5.4 Protein Expression Patterns
The following figures show Western blots of one representative experiment
(one out of three). The densitometric data shows the mean of all three
experiments with the relative signal values, standardized on the respective
β-actin signal and compared in relation to each other. The signal value is
equal to the relative density and gray scale of the antibody signal on the
Western blot.
5.4.1 CD2 and Nck
The densitometric evaluation of the Western blot showed a fairly stable
expression of Nck with little or no influence of stimulation with anti-CD2
or anti-CD3 antibodies. There was no significant difference between
unstimulated, anti-CD2 stimulated and anti-CD3 stimulated cells.
Figure 5.15: NCK1/2 densitometric data
Time Stimulation Signal Mean SD
24h neg 1,5673 0,0336
CD2 1,5361 0,0628
CD3 1,5281 0,0548
48h neg 1,5127 0,0341
CD2 1,5501 0,0242
CD3 1,5362 0,0297
72h neg 1,5553 0,0326
CD2 1,5234 0,0167
CD3 1,5049 0,0469
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Figure 5.16: Western blot of a whole cell lysate (WCL) with protein levels
of NCK (upper lane), and β-actin as a standard (lower lane). The exposure
time was 5 minutes in this case, and shows solid, clearly defined NCK bands,
as well as a consistent protein concentration, judging by the regular β-actin
bands.
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5.4.2 CD2 and CD200
The densitometric evaluation of the CD200 Western blots showed a stable
but very weak expression of CD200 with little or no influence of
stimulation with anti-CD2 or anti-CD3 antibodies. There was no
significant difference between unstimulated, anti-CD2 stimulated and
anti-CD3 stimulated cells. Each lane was measured in relation to its
β-actin signal and compared in relation to each other.
Figure 5.17: CD200 densitometric data
Time Stimulation Signal Mean SD
24h neg 0,7172 0,0951
CD2 0,7561 0,1525
CD3 0,6998 0,1054
48h neg 0,7278 0,1417
CD2 0,6412 0,0458
CD3 0,7514 0,0944
72h neg 0,7524 0,0388
CD2 0,7542 0,1118
CD3 0,7433 0,0704
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Figure 5.18: Western blot of a whole cell lysate (WCL) with protein levels
of CD200 (upper lane), and β-actin as a standard (lower lane).
5.4.3 CD2 and αPak
The densitometric evaluation of the αPak Western blot showed a time-
dependent, and slight stimulus-dependent (neg/CD2/CD3) expression pat-
tern. Each lane was measured in relation to its β-actin signal and compared
in relation to each other.
Figure 5.19: αPak densitometric data
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Time Stimulation Signal Mean SD
24h neg 1,0791 0,1264
CD2 1,2733 0,1980
CD3 1,2771 0,1428
48h neg 1,1998 0,0606
CD2 1,3016 0,1762
CD3 1,3258 0,2026
72h neg 0,1619 0,0498
CD2 0,5398 0,1519
CD3 0,7155 0,2614
Figure 5.20: Western blot of a whole cell lysate (WCL) with protein levels
of αPak (upper lane), and β-actin as a standard (lower lane).
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5.4.4 CD2 and CD137L
The densitometric evaluation of the CD137L Western blot showed a strong
time-dependent, and slight stimulus-dependent (neg/CD2/CD3) expression
pattern. Each lane was measured in relation to its β-actin signal and com-
pared in relation to each other.
Figure 5.21: CD137L densitometric data
Time Stimulation Signal Mean SD
72h neg 0,7010 0,1513
CD2 1,4830 0,3385
CD3 1,6995 0,3568
Figure 5.22: Western blot of a whole cell lysate (WCL) with protein levels
of CD137L (upper lane), and β-actin as a standard (lower lane).
Discussion and Outlook
The role of CD4+ helper cells in immune and autoimmune processes raised
more and more interest over the last twenty years since their first charac-
terization in the late 80s. [14]. It soon became apparent that the immune
system is more than just a broad sword which is either raised against in-
truders or securely sheathed, but rather a versatile applicable scalpel, which
ipso facto needs a highly regulated hand that leads it. At this point, many
fine-regulatory mechanisms are still obscure, especially when it comes to co-
stimulation and crosstalk between subpopulations of the immune system.
In this work we tried to shed light on the issue of CD2-(co)-stimulation
in the context of T-cell signalling and anergy. More precisely we looked
at the protein expression patterns of four different alleged targets, namely
NCK1/2, CD200, αPak and CD137L which showed an increased mRNA
expression in previous experiments following stimulation with anti-CD2 an-
tibodies. Within the scope of this project we isolated CD4+ / CD25- /
HLA-DR- Helper-cells from the blood of volunteers, we then stimulated the
cells with anti-CD2 antibodies and observed the change of protein expression
over a time period of three days with time points at 24, 48 and finally 72
hours. What we found was an altered expression pattern in two of our target
proteins (CD137L and αPak), a steady and unchanged expression of NCK
and finally a surprisingly low level of CD200 in the cell lysates.
6.1 T-cell Anergy and CD2
Anergy is a state of indifference, in which T-cells actively repress TCR sig-
nalling as well as the production of IL-2 [75]. This process is vital for im-
munological tolerance to self and foreign antigens, consequently, the disabil-
ity for T-cells to properly enter the state of anergy may lead to autoimmune
issues. The underlying mechanisms which lead T-cells into anergy are not
fully understood yet, but it has been suggested that signalling via TCR (sig-
nal 1), in absence of a co-stimulatory signals from CD28 (signal 2) leads to
T-cell anergy [76], meaning that TCR-signalling alone triggers a cascade of
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inhibitory signals, leading to a metabolic stasis, which can only be suspended
by joint signalling of both TCR and CD28. This issue demonstrates the im-
portance of co-stimulatory molecules in the regulation of immune functions,
but is also true for other co-stimulatory molecules. The binding of CD28 to
either B7-1 or B7-2 for example, can prevent T-cells from entering anergy
by inducing IL-2 production and proliferation. In case of CD2, it has been
shown that in anergic cells, the CD2R epitope disappears, rendering it unre-
sponsive to signals. Upon exposure to IL-2, the epitope is exposed again and
the CD2/LFA-3 signalling is sufficient to shake the cell out of anergy [77].
6.2 CD2 and the Actin Cytoskeleton
Most recent literature suggests CD2’s involvement in cytoskeletal rearrange-
ments via interaction with binding proteins, recruited to its cytosolic tail [54]
[52] [53]. More specific, the proline rich sequences of the tail are a potential
docking site for a vast number of SH3 domain carrying targets. Nck as a
SH3 / SH2 adaptor protein falls into that category and raised our atten-
tion after the initial finding that the NCKs mRNA was slightly upregulated
following anti-CD2 mAb stimulation (see Fig 4.1). Additionally, Buday et
al. [68] suggested a connection between Nck and the actin skeleton by show-
ing that its ability to recruit members of the Ser/Thr kinase family (such as
αPak) to the cell membrane via its SH2 domain. As our data shows in figure
5.16, the protein expression levels of NCK, did not seem to alter much after
stimulation with anti-CD2 antibodies, whereas the levels of αPak did. We
hypothesize that the slightly increased expression of Nck’s mRNA following
αCD2 stimulation is important for the cell, in order to have enough tran-
script to quickly replenish Nck during cell-signalling. Since the interaction
between CD2 and CD58 is furthermore important for „scanning“ [48], which
involves intense rearrangements of the cytoskeleton (capping, focal adhesions
etc.), it would make sense to keep a high level of NCK transcript in the back
hand for overcoming NCK shortage. Nevertheless, Nck as a protein is not
upregulated after a CD2 stimulus, and the mRNA data shows only a slight
increase compared to the unstimulated control. Whether Nck plays a part
on the proximal end of the CD2 signalling cascade or not, remains unclear
for the time being. Figure 6.1 shows a simplistic scheme of Nck and Pak
interaction, showing a RTK as the source of the signal. In case of CD2, Nck
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Figure 6.1: Nck recruits Pak to a growth factor receptor. The Pak kinase
is then able to either directly or indirectly (via Pix) regulate cytoskeletal
rearrangements by activating of multiple signalling pathways [68]
would bind to the cytosolic tail via its SH3 domain instead of the shown
SH2 domain. Compared to the mRNA levels of Nck measured, αPak did
show a much higher expression rate (see Fig 4.2) after stimulation via CD2
or CD3. As figure 5.20 illustrates, the protein levels of αPak are stable over
48 hours upon stimulation and rapidly decrease again after 72 hours. These
findings indicate a correlation between T-cell stimulation via CD2/CD3 and
regulation of αPak transcription and translation on some level. Be as it
may, this is probably not limited to CD2 stimuli, due to the nature of the
Pak kinases as important regulators in several other pathways and immune
functions [65] [66]. Interestingly though is the fact that CD2 seems to have
a greater impact upon the transcriptional regulation of αPak than CD3 has.
Regarding protein levels, they seem to be almost equally able to stimulate
the production of this kinase.
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6.3 CD2 as a regulator of T-cell anergy
Despite its role as a co-inducer for T-cell activation, there is vague evi-
dence [78] that CD2 is also involved in regulatory pathways yet to be eluci-
dated. In our preliminary mRNA data, amongst others, two genes showed
an increased transcription rate after CD2 stimulation, which immediately
caught our attention. One was a glycoprotein, seemingly involved in au-
toimmune disorders and regulation of immune functions [62], termed CD200
(OX2, MOX2) and the other, was the ligand to a tumor necrosis factor super-
family receptor, termed CD137L. As stated above, the lack of co-stimulatory
signals during T-cell activation leads to a state of unresponsiveness and an-
ergy. Besides CD28, the probably best characterized co-stimulatory molecule
in this context, there are many other possible co-stimulatory interactions.
CD137L amongst other members of the TNF receptor superfamily is able
to induce co-stimulatory signals [79] ensuring survival and differentiation
of T-cells (both CD4+ and CD8+). While CD200 was known to be ex-
pressed on activated T-cells [61], CD137L was thought to be only expressed
on APCs and in exceptional cases on T- and B-cell lymphomas [59]. In lat-
ter case, the expression of receptor and ligand prolongs their survival and
helps to induce proliferation, since studies have shown that the interaction
of CD137 and CD137L can enhance the production of IL-2 and IL-4 by
CD4+ cells [79], and therefore enhance the overall proliferation. Addition-
ally CD137 signalling is further more important to rescind the suppressive
effects, imposed by CD4/CD25+ regulatory T-cells [80], meaning that the
additional upregulation of the ligand after 72h might be a countermeasure
to evade anergy or extended suppression. Especially in graft rejection this
plays an important role, since it has been shown that the jamming of the
interaction between CD137 and its ligand CD137L significantly increased
the overall allograft survival [81]. It was difficult to initially detect CD137L
on our Western blots since it seems to be a protein expressed only after a
long time activation of Th-cell populations. Nevertheless the mRNA data
(Fig 4.3) shows an increase in transcription after two hours, yet the protein
is not detectable until after 72 hours (5.22). In the context of CD2 sig-
nalling, this might mean that CD137L is upregulated after approximately 72
hours to evade anergy induced by long term stimulation with anti-CD2 mAb.
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CD200 is known to be expressed on activated T-cells [61], and seems to
play an important role in the downregulation of excessive immune responses,
such as infections with the influenza virus [82]. Additionally it plays a major
role as an immunosuppressive molecule which can be found overexpressed in
many tumor forms [83], where it modulates the function of T-cells attacking
the tumor tissue. Interestingly, in contrast to the mRNA data (Fig 4.4),
the Western blots (Fig.5.18) only showed very low concentrations of CD200
detectable in the cell lysate. There are many possible reasons for this out-
come, since mRNA does not necessarily have to be translated directly into
protein. Therefore large amounts of the transcript might just exist as a
backup for a period of time and are then degraded again. Additionally, it is
possible that the time points we picked were too late to detect an increase in
CD200, since the mRNA detection was conducted two hours after stimula-
tion, whereas the protein expression was examined 24, 48 and 72 hours after
stimulation. Nevertheless, since the CD200 - ligand (CD200R1) interaction
plays an important part in the general understanding of autoimmune diseases
and immune modulation [61], it seems important to confirm the interaction
between CD2 and CD200, since this „backdoor“ might help to develop new
therapies for autoimmune issues as well as graft rejection and other diseases
caused by a T-cell frenzy.
6.4 CD2 as a therapeutic target?
An anti-CD3 mAb is already in use as a therapeutic drug (OKT3), to induce
T-cell anergy and prevent skin graft rejection. The potential of CD2 as a
therapeutic target is growing ever since its discovery as a co-stimulatory and
regulatory molecule. The blocking of CD2-LFA-3 signalling can prolong an-
ergy in vitro [77], but not permanently, due to several possible co-stimulatory
signals which can be induced by B-cells or APCs or a longer exposure to IL-
2. On the other hand, without the blocking of CD2, the anergic effects
only last for a maximum of 7 days. One therapeutic CD2 drug (Alefacept)
is already in use for the treatment of psoriasis, an inflammatory skin dis-
ease. Alefacept is basically an immunoglobulin consisting of an extracellular
CD2-binding portion of the human LFA-3 linked to the Fc portion of human
IgG1. This design, allows it to effectively bind to cells with upregulated
CD2 clusters, while the Fc part binds to the FcγRIII receptor on NK cells,
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leading to antibody dependent cellular cytotoxy (ADCC) thus removing cells
with an upregulated CD2 expression. We were able to show that stimulation
with anti-CD2 antibodies increased the expression of a protein involved in
T-cell activation, and anergy, namely CD137L. CD200 which is important
to downregulate certain immunefunctions to prevent autoimmunity, showed
an increased mRNA transcription rate, but was not highly expressed on a
protein level. These two proteins are allready under investigation as im-
munoregulatory co-stimulators, therefore it would be interesting to reveal
the mechanisms between CD2 stimulation and these the transcriptional con-
troll of these two proteins, to broaden the possibilities of an therapeutic
approach for the treatment maladies caused by cocky T-cells. However there
is still much left to clarify within the issue of CD2 induced direct or indi-
rect (via upregulated co-stimulatory molecules) anergy, therefore only rough
speculations are applicable at the moment.
6.5 General Outlook
To further define the task(s) assigned to CD2 in the immunological synapse,
it seems necessary to further investigate known and suggested downstream
partners, look into additional proteins, which displayed increased mRNA
levels, and check their expressions. Concerning our four proteins, it would
make sense to identify intermediaries to fully disclose the mechanism behind
CD2 induced activation or anergy. Additionally, in case of CD200, it would
be important to pick earlier timepoints for lysing the cells, with intervals
starting with four hours after CD2 stimulus (the point where mRNA levels
were measured) followed by 8 and 12 hour lysing of the cells, which would
clarify whether the mRNA is in fact translated into protein or not. For
CD137L the opposite would apply, since this protein is only expressed after
72 hours. Therefore we would suggest to shift the time points to 48, 72 and
maybe 96 hours. In addition, the FACS dot blots of the αCD2 stimulation
(see Fig 5.9) indicate that we were only able to stimulate a relatively small
population out of all CD4+ / CD25- / HLA-DR - T-cells, since not all CD3
positive cells expressed CD69 following stimulation with anti-CD2 antibod-
ies. This circumstance would be a possible explanation for the poor yield in
CD200 protein. Even so, by dealing with such small subpopulations of T-
cells it seems difficult to harvest enough cell material for the detailed study
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of specific protein expression profiles. In order to do so, more source material
(blood) would be necessary, which of course is limited, or the methods for de-
tection have to be refined to detect lower amounts of protein. Possibilities for
this or to substantiate interaction partners within the CD2 pathway(s), and
further illume the regulatory mechanisms behind this receptor would be to
perform co-immunoprecipitations, yeast-two-hybridassays, or mTRACKing
(not published yet) assays.
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List of Abbrevations
ADCC antibody dependent cellular cytotoxicity
AID autoinhibitory domain
APC antigen presenting cell
APs ammonium persulfate
BCR B-cell receptor
BLR-1 Burkitt-lymphoma receptor 1
CD cluster of differentiation
CD2BP1 CD2-binding protein 1
CIA collagen induced arthritis
CLP common lymphocyte precursors
CMS human CD2AP
Cool cloned out of library
CRIB Cdc42 and Rac interactive binding
CTLA-4 cytotoxic T lymphocyte-associated antigen 4
CXCL CXC chemokine ligand
CXCR5 CXC-motive chemokine recepotor 5
EAE expermiental autoimmune encephalomyelitis
ECL enhanced chemi-luminescence
EDTA ethylene diamine tetraacetic acid
EGF epidermal growth factor
FACS fluorescence activated cell sorting
FITC fluorescein-isothiocyanate
Foxp3 forkhead box P3 transcription factor
GC germinal center
GITR glucocorticoid induced tumor necrosis factor receptor family
related gene
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HLA-DR human leucocyte antigen-DR
HSV herpes simplex virus
IBD inflammatory bowel disease
ICAM intercellular adhesion molecule
IFN interferon
Ig immunoglobulin
IL interleukin
ImmB immature B-cell
IS immunological synapse
ITAM immunoreceptor tyrosine-based activation motif
iTreg inducible T regulator
LAG-3 lymphocyte activation gene-3
LFA leukocyte function antigen
LPTC lamina propria T-cells
mAb monoclonal antibody
MAC membrane attack complex
MHC major histocompatibility complex
MNC mononuclear cells
mRNA messenger ribonucleic acid
Nck non-catalytic region of tyrosine kinase adaptor protein
NFAT nuclear factor of activated T-cells
NK natural killer cell
nTreg natural T regulator
Pix Pak interacting exchange factors
PBD p21 GTPase binding domain
PBS(-T) phosphate buffered saline (-tween 20)
PE phycoerythrin
pMHC peptide bound MHC
PDGF platelet derived growth factor
PRR pattern recognition receptor
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PTK protein tyrosine kinases
RA rheumatoid arthritis
PAK p21 activated kinase
PMSF phenylmethylsulfonyl fluoride
RPMI Roswell Park Memorial Institute
SH2 Src homology 2
SLP-76 SH2 domain containing leukocyte protein of 76 kDa
SMAC supra molecular activation cluster
STAT signal transducer and activator of transcription
Tc cytotoxic T-cells
TCR T-cell receptor
Tfh follicular helper T-cells
TGF transforming growth factor
Th T-helper-cells
TLR toll-like receptor
TNF tumor necrosis factor
WASP Wiskott-Aldrich syndrome protein
V(D)J variable diverse and joining
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Appendix
8.1 CDs
CD2 T11, LFA-2, E-rosette receptor
expressed on T-cells, thymocytes, NK cells
molecular weight: 45-58 kDa
function: adhesion, costimulation, binds to Lck intracellularly, binds to
CD58 (LFA-3).
CD3 T3
expressed on T-cells, thymocytes (common T-cell marker)
molecular weight: Three peptides: 20-28
function: associated with the T cell antigen receptor, signal transduction.
CD4 T4, L3T4
expressed on thymocytes, T cells, monocytes, macrophages
molecular weight: 55 kDa
function: co-receptor for MHC class II molecules, signal transduction.
CD8a,b T8, Lyt2,3
expressed on a thymocyte subpopulation, CTL, Treg cells in the periphery
molecular weight: CD8a: 38 kDa; CD8b: 30kDa
function: Co-receptor for MHC class I molecules.
CD13 Aminopeptidase N
expressed on myelomonocytic cells
molecular weight: 150-170 kDa
function: Zink- metalloproteinase, enzyme activity
CD14 LPS receptor
expressed on myelomonocytic cells
molecular weight: 53-55 kDa
function: Receptor for lipopolysaccharid- complex and lipopolysaccharid-
binding protein (LBP)
CD16 FcgRIII, FcRIIIA, FcRIIIB
expressed on neutrophils, NK cells, macrophages
molecular weight: 50-80 kDa
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function: deep-affine Fc receptor, mediating phagozytosis and antibody de-
pendend cellular cytotoxicity (ADCC)
CD19
expressed on B cells
molecular weight: 95 kDa
function: in a complex with CD21 (CR2) and CD81 (TAPA-1); co-receptor
for B cells
CD25
IL-2Ra, Tac
expressed on activated T cells, regulatory T cells, B cells und monocytes
molecular weight: 55 kDa
function: IL-2 receptor α-chain
CD69
Activation induction molecule (AIM)
expressed on activated T and B cells, activated macrophages and NK cells
molecular weight: 28, 32 Homodimer
function: unknown, early activation marker
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